Mdm2-p53 Signaling in Tissue Homeostasis and the DNA Damage Response: A Dissertation by Gannon, Hugh S.
University of Massachusetts Medical School 
eScholarship@UMMS 
GSBS Dissertations and Theses Graduate School of Biomedical Sciences 
2012-06-28 
Mdm2-p53 Signaling in Tissue Homeostasis and the DNA 
Damage Response: A Dissertation 
Hugh S. Gannon 
University of Massachusetts Medical School 
Let us know how access to this document benefits you. 
Follow this and additional works at: https://escholarship.umassmed.edu/gsbs_diss 
 Part of the Amino Acids, Peptides, and Proteins Commons, Animal Experimentation and Research 
Commons, Cancer Biology Commons, Cells Commons, Genetic Phenomena Commons, Neoplasms 
Commons, and the Tissues Commons 
Repository Citation 
Gannon HS. (2012). Mdm2-p53 Signaling in Tissue Homeostasis and the DNA Damage Response: A 
Dissertation. GSBS Dissertations and Theses. https://doi.org/10.13028/sfjc-xh51. Retrieved from 
https://escholarship.umassmed.edu/gsbs_diss/631 
This material is brought to you by eScholarship@UMMS. It has been accepted for inclusion in GSBS Dissertations and 
Theses by an authorized administrator of eScholarship@UMMS. For more information, please contact 
Lisa.Palmer@umassmed.edu. 
  
 
MDM2-P53 SIGNALING IN TISSUE HOMEOSTASIS  
AND THE DNA DAMAGE RESPONSE 
 
 
A Dissertation Presented  
By 
Hugh S. Gannon Jr. 
 
Submitted to the Faculty of the 
University of Massachusetts Graduate School of Biomedical Sciences, Worcester 
in partial fulfillment of the requirements for the degree of 
 
 
 
 
DOCTOR OF PHILOSOPHY 
June 28, 2012 
PROGRAM IN CELL BIOLOGY 
 
 
 
 
 
Mdm2-p53 Signaling in Tissue Homeostasis and the DNA Damage Response 
A Dissertation Presented  
By 
Hugh S. Gannon Jr. 
Approved as to style and content by: 
 
Hong Zhang, Ph.D., Chair of Committee 
 
Roger Davis, Ph.D., Member of Committee 
 
Michelle Kelliher, Ph.D., Member of Committee 
 
Brian Lewis, Ph.D., Member of Committee 
 
Philip Hinds, Ph.D., Member of Committee 
 
Stephen N. Jones, Ph.D., Thesis Advisor 
 
Anthony Carruthers, Ph.D.  
Dean of the Graduate School of Biomedical Sciences 
 
Cell Biology 
June 28, 2012 
TABLE OF CONTENTS 
 
COPYRIGHT NOTICE                  i 
DEDICATION                  ii 
ACKNOWLEDGEMENTS                   iii 
SUMMARY                             iv 
LIST OF TABLES                 vi 
LIST OF FIGURES                vii 
CHAPTER I:  Introduction                  1 
1.1 Foreword                   2 
1.2 The p53 Transcription Factor                                                     3 
1.3 The Role of p53 in Tumor Suppression               5 
1.4 Mdm Proteins Tightly Regulate p53 In Vivo               7  
1.5 Mdm2 and MdmX conditional knockout mice                      12 
1.6 Mdm2 and MdmX transgenic mice               14 
1.7 Mdm2 and MdmX knock-in mice: exploring RING domain function       17 
1.8 Mdm2 and MdmX knock-in mice: exploring cellular stress responses      20 
1.9 Aims of this Dissertation                         22 
       
CHAPTER II: MDM2-P53 SIGNALING REGULATES EPIDERMAL STEM 
CELL SENESCENCE AND PREMATURE AGING 
PHENOTYPES IN MOUSE SKIN                                                    24 
 
FOREWORD                25 
INTRODUCTION                25 
RESULTS                29 
DISCUSSION                43 
MATERIALS AND METHODS              48 
 
CHAPTER III: ATM PHOSPHORYLATION OF MDM2 SER394 REGULATES 
THE AMPLITUDE AND DURATION OF THE DNA DAMAGE 
RESPONSE IN MICE                                                          53 
 
FOREWORD                54 
INTRODUCTION                54 
RESULTS                58 
DISCUSSION                92 
MATERIALS AND METHODS              96 
 
CHAPTER IV:   UNPUBLISHED AND ONGOING WORK                    101 
 
FOREWORD              102 
INTRODUCTION              102 
RESULTS              104 
DISCUSSION              109 
MATERIALS AND METHODS            111 
CHAPTER V: GENERAL DISCUSSION           113 
REFERENCES               126 
 
 
 
i 
COPYRIGHT NOTICE 
 
Parts of this dissertation have been presented in the following publications: 
Gannon, H.S., and Jones, S.N. Genetic analysis of MDM-p53 signaling in development, 
cell growth, and tumorigenesis. Genes and Cancer. In press. 
 
Gannon, H.S., Woda, B.A., and Jones, S.N. (2012). ATM phosphorylation of Mdm2 
Ser394 regulates the amplitude and duration of the DNA damage response in mice. 
Cancer Cell. 21:668-679. 
 
Gannon, H.S., Donehower, L.A., Lyle, S., and Jones, S.N. (2011). Mdm2-p53 signaling 
regulates epidermal stem cell senescence and premature aging phenotypes in mouse skin. 
Developmental Biology. 353:1-9. 
 
Additional Relevant Publications:
Coles, A. H., Gannon, H., Cerny, A., Kurt-Jones, E., and Jones, S. N. (2010). Inhibitor 
of growth-4 promotes IκB promoter activation to suppress NF-κB signaling and innate 
immunity. Proc Natl Acad Sci U S A. 107: 11423-11428. 
 
Mason, E. F., Zhao, Y., Goraksha-Hicks, P., Coloff, J. L., Gannon, H., Jones, S. N., and 
Rathmell, J. C. (2010). Aerobic glycolysis suppresses p53 activity to provide selective 
protection from apoptosis upon loss of growth signals or inhibition of BCR-Abl. Cancer 
Research. 70: 8066-8076. 
 
Sluss, H. K., Gannon, H., Coles, A. H., Shen, Q., Eischen, C. M., and Jones, S. N. 
(2010). Phosphorylation of p53 serine 18 upregulates apoptosis to suppress Myc-induced 
tumorigenesis. Molecular Cancer Research. 8: 216-222. 
 
 
 
 
ii 
 
 
 
 
DEDICATION 
 
This dissertation is dedicated to my wife Kristina.   
You have been and always will be my inspiration and constant.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
iii 
 
 
 
ACKNOWLEDGEMENTS 
 
I am extremely grateful to the many people that have contributed to my 
development as a graduate student.  I would like to particularly thank my thesis mentor, 
Dr. Stephen Jones, whose teaching and direction helped me not only to learn numerous 
experimental techniques, but, more importantly, taught me how to think as a scientist.  
Additionally, I would like to thank the members of the Jones lab, past and present, and 
the members of my TRAC for their answers to my questions and helpful input on the 
problems I faced along the way.  Finally, I would like to thank my family and friends for 
all their love and support throughout my life.          
   
 
 
 
 
 
 
 
 
 
 
 
iv 
SUMMARY 
 
The p53 transcription factor responds to various cellular stressors by regulating 
the expression of numerous target genes involved in cellular processes such as cell cycle 
arrest, apoptosis, and senescence.  As these downstream pathways are harmful to the 
growth and development of normal cells when prolonged or deregulated, p53 activity 
needs to be under tight regulatory control.  The Mdm2 oncoprotein is the chief negative 
regulator of p53, and many mouse models have demonstrated that absence of Mdm2 
expression leads to constitutive p53 activation in a variety of cell types.  While 
unregulated p53 can be deleterious to cells, functional p53 is essential for tumor 
suppression; as many human cancers harbor p53 mutations and p53 knockout mice 
rapidly develop spontaneous tumors.  Therefore, the mechanisms that control p53 
regulation by Mdm2 are critical to ensure p53 activity in the appropriate cellular context. 
 
Many genetically engineered mouse models have been created to analyze p53 and 
Mdm2 functions and these studies have yielded valuable insights into their physiological 
roles.  This dissertation will describe the generation and characterization of novel mutant 
Mdm2 mouse models and their use to interrogate the roles of p53-Mdm2 signaling in 
tissue homeostasis and cell stress responses.  Deletion of Mdm2 in epidermal progenitor 
cells of the skin and hair follicles resulted in progressive hair loss and decreased skin 
integrity, phenotypes that are characteristic of premature aging.  Furthermore, p53 protein 
levels, p53 target gene expression, and cellular senescence were all upregulated in the 
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skins of these mice, and epidermal stem cell numbers and function were diminished.  
These results indicate that Mdm2 is necessary to limit p53 activity in adult tissues to 
ensure normal stem cell function. 
 
Additional mouse models used to determine the role of Mdm2 phosphorylation 
will also be presented.  DNA damage triggers an extensive cellular response, including 
activation of the ATM kinase.  ATM activity is necessary for p53 protein stabilization 
and, therefore, p53 activation, but in vivo evidence suggests that phosphorylation of p53 
itself had little effect on p53 stability.  ATM was previously shown to phosphorylate 
MDM2 at serine residue 395 (394 in mice), and we generated knock-in mutant mouse 
models to study the role of this posttranslational modification in vivo.  Absence of this 
phosphorylation site led to greatly diminished p53 stability and function in response to γ-
irradiation and increased spontaneous tumorigenesis in mice.  Conversely, a phospho-
mimic model demonstrated prolonged p53 activation in cells treated with γ-irradiation, 
which revealed that phosphorylation of this Mdm2 residue controls the duration of the 
DNA damage response.  Therefore, these mouse models have uncovered new roles for 
the p53-Mdm2 regulatory axis in vivo and will be useful reagents in future studies of 
posttranslational modifications in oncogene and DNA damage-induced tumorigenesis. 
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INTRODUCTION 
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1.1 Foreword 
The p53 tumor suppressor protein and MDM oncoproteins (Mdm2 and MdmX) 
constitute a signaling axis that controls the response of cells to a wide variety of genetic 
or metabolic stresses.  The p53 transcription factor alters the expression of numerous 
genes whose products affect proliferation, senescence, cellular metabolism, apoptosis, 
and DNA repair (Vousden and Lu, 2002; Vousden and Ryan 2009; Sengupta and Harris, 
2005).  By activating these various effector pathways, p53 prevents the transmission of 
mutations to subsequent generations of cells, thereby suppressing tumorigenesis at the 
organismal level.  Chief among the negative regulators of p53 are the MDM oncoproteins 
Mdm2 and MdmX.  These MDM proteins complex with the p53 transcription factor and 
inhibit p53-transactivation of various p53-target genes, including Mdm2 and MdmX 
(Figure 1.1).  By inhibiting p53 activity in the cell, these MDM proteins facilitate the 
growth of normal cells required for embryonic development and adult tissue 
maintenance.  Many mouse models bearing genetic alterations in Mdm2 and MdmX have 
been generated to probe the role of the Mdm2-p53 signaling axis in development, in 
tissue homeostasis, in aging, and (especially) in cancer.  Analysis of these mouse models 
has provided strong genetic evidence that support preceding in vitro studies of MDM 
protein functions while disproving others. 
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Figure 1.1: The p53-Mdm2-MdmX signaling pathway. 
 
1.2 The p53 Transcription Factor 
The p53 protein was initially discovered to be overexpressed and complexed with 
the large T antigen in a variety of simian virus 40 (SV40)-transformed mammalian cell 
lines (Chang et al., 1979; Kress et al., 1979; Lane and Crawford, 1979; Linzer and 
Levine, 1979; Melero et al., 1979).  Further experimentation showed that introduction of 
p53 cDNA cooperated with Ha-ras to transform rat embryonic fibroblasts (Eliyahu et al., 
1984; Parada et al., 1984).  These initial results suggested that p53 was an oncogene, as 
increased p53 correlated with increased transformation potential in cells.  However, it 
was later determined that these original p53 cDNA constructs contained p53 inactivating 
mutations.  It was subsequently found that wild-type (WT) p53 cDNA was unable to 
cooperate to transform cells and p53 expression was frequently lost in mutagenesis-
induced tumor mouse models (Eliyahu et al., 1989; Finlay et al., 1989; Mowat et al., 
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1985; Munroe et al., 1988), which ultimately led to succeeding studies that described p53 
as a tumor suppressor.   
 
The p53 protein was shown to bind DNA in a site-specific manner (Kern et al., 
1991; Funk et al., 1992; El-Deiry et al., 1992), and further analyses revealed that p53 is a 
transcription factor that activates the expression of numerous target genes involved in 
various cell signaling pathways including cell cycle arrest, senescence, apoptosis, DNA 
repair, and cellular metabolism.  One of the first p53-inducible targets to be discovered, 
the cyclin dependent kinase inhibitor p21, was found to be necessary for p53-dependent 
cell cycle arrest (El-Deiry et al., 1993; Brugarolas et al., 1995).  The p21 protein has also 
been shown to be a key mediator of the cellular senescence response, an irreversible cell 
cycle arrest that is dependent on p53 functions (Harvey and Levine, 1991; Fang et al., 
1999; Wang et al., 1999; Chang et al., 2000).  The transcriptional activity of p53 is also 
necessary to induce the expression of multiple genes involved in apoptosis.  These 
include, but are not limited to, the pro-apoptotic Bcl-2 family members Bax (Miyashita 
and Reed, 1995), Noxa (Oda et al., 2000), and Puma (Nakano and Vousden, 2001; Yu et 
al., 2001).  The protein products of these genes trigger the pro-apoptotic caspase cascade 
after permeabilization of the mitochondrial membrane releases cytochrome c into the 
cytosol (Bossy-Wetzel and Green, 1999).  Novel p53-dependent target genes and 
signaling pathways are constantly arising in the literature, and the relative contribution of 
each signaling pathway to the tumor suppressive function of p53 is still under debate (Li 
et al., 2012).   
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1.3 The Role of p53 in Tumor Suppression 
The importance of p53 in tumor suppression is further evidenced by the fact that 
over 50% of all human cancers have a mutated p53 gene (Levine, 1997; Soussi and 
Beroud, 2001).  Likewise, cancers that harbor wild type p53 often have a compromised 
p53-dependent response due to mutations in positive regulators or gene amplification of 
negative regulators of p53, demonstrating that p53 function is critical for tumor 
suppression (Levine, 1997).  Genetic disruption of p53 in mice enabled the necessity of 
p53 tumor suppression to be truly be assessed at the physiological level.  
 
Because early in vitro studies suggested that p53 was a critical regulator of the 
cell cycle (Baker et al., 1990; Diller et al., 1990; Stürzbecher et al., 1990; Bischoff et al., 
1990), p53 knockout mice were anticipated to have severe defects in embryonic 
development and cellular growth.  Surprisingly, p53-null mice proved to be viable and 
physically indistinguishable from wild-type littermates at an early age (Donehower et al., 
1992).  However, these mice rapidly developed spontaneous tumors, confirming a critical 
role for p53 in tumor suppression.  These tumors were mostly lymphomas (chiefly T-cell 
in origin), with some incidence of sarcomas and other tumor types.  Subsequent analysis 
of primary fibroblasts derived from this model revealed that p53 reduction or deletion 
could upregulate cell proliferation and inhibit the growth arrest of cells exposed to DNA 
damaging agents and other growth arrest signals, revealing a role for p53 in the DNA 
damage response (Harvey et al., 1993).  
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Other groups developed additional p53 knockout mouse models that also formed 
spontaneous tumors with a relatively similar spectrum (Jacks et al., 1994; Armstrong et 
al., 1995).  These subsequent studies observed that a subset of p53-null mice die in utero 
due to exencephaly (Armstrong et al., 1995), and that thymocyte apoptosis normally 
induced by exposure to ionizing radiation was greatly compromised by p53 deficiency, 
underscoring a critical role for p53 in regulating cell death in response to DNA damage 
(Lowe et al., 1993).  These p53-/- mice were also more susceptible to tumorigenesis 
induced by ionizing radiation (Kemp et al., 1994).  Interestingly, the tumorigenic 
phenotype of p53+/- mice differed from p53-/- mice, with heterozygous mice displaying 
neoplasia at a later age and forming mostly sarcomas, with a lessor percentage of 
lymphomas and other tumor types.  As anticipated from earlier studies of familial cancer 
syndromes, loss of heterozygosity (LOH) for the wild-type p53 allele could be detected in 
tumors isolated from p53+/- mice (Jacks et al., 1994).  However, subsequent work 
determined that only half of the tumors isolated from p53-heterozygous mice undergo 
LOH, suggesting that perturbation of other members of the p53 signaling axis might 
account for functional loss of p53 in these tumors or that a simple reduction in p53 
function is sufficient to increase the susceptibility of the cell to tumorigenesis 
(Venkatachalam et al., 1998).  Collectively, these initial studies of p53-null and p53-
heterozygous mice demonstrated the importance of p53 in governing the DNA damage 
response and in suppressing tumorigenesis, validating the use of mouse modeling as a 
powerful tool to study both tumor suppressor genes and the p53 signaling pathway 
particularly in vivo.   
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Numerous labs have continued to utilize p53-deficient and p53 knock-in mouse 
models to successfully uncover multiple roles for p53 in the regulation of cell growth and 
tumorigenesis.  These p53 models have greatly assisted in our understanding of the 
tumorigenic effects of p53 loss of function and gain of function mutations, and have 
highlighted roles for p53 in other biological settings, including reproduction, 
development, and aging.  Many of these in vivo p53 functions are discussed in several 
recent reviews of p53 mouse model phenotypes (Donehower, 2009; Lozano, 2009; 
Donehower and Lozano, 2009; Toledo and Wahl, 2006). 
 
1.4 Mdm Proteins Tightly Regulate p53 In Vivo 
Since p53 activity limits the capacity of cells to grow and function, p53 protein 
levels and functions must be kept under tight check in both non-damaged cells and in 
cells that have repaired their damaged genomes.  Mdm2 was one of the earliest cellular 
negative regulators of p53 to be discovered and studied in depth (Momand et al., 1992; 
Oliner et al., 1993; Chen et al., 1995).  Mdm2 was identified and cloned as one of several 
genes present on a double minute chromosome that was isolated from a spontaneously 
transformed 3T3 cell line (Fakharzadeh et al., 1993).  Subsequent transfection studies 
revealed that Mdm2 interacts with p53, sterically hindering the amino-terminal activation 
domain of the p53 protein and sequestering p53 away from target gene promoters in vitro 
(Momand et al., 1992; Oliner et al., 1993; Chen et al., 1995; Freedman and Levine, 1998; 
Geyer et al., 2000).  The Mdm2-p53 interaction also blocks the ability of p53 to bind 
transcriptional cofactors, thereby directly inhibiting its function as a transcription factor 
(Iwakuma et al., 2003).  This negative regulation ensures that cellular functions are not 
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inappropriately perturbed by p53-dependent cell cycle arrest or apoptosis under normal 
conditions.  Additionally, the Mdm2 gene is a target of the p53 transcription factor, 
forming a tight negative regulatory loop that quickly returns p53 protein and activity to 
basal levels (Juven et al., 1993; Wu et al., 1993).  
 
 Interest in the oncogenic potential of Mdm2 was greatly increased when the 
Mdm2 gene was found amplified in a significant fraction of human sarcomas (Oliner et 
al., 1992) and human tumors of the lung, breast, bone, and soft tissues (Momand et al., 
1998).  It is thought that Mdm2 constitutively inhibits wild-type p53 in these tumors, as 
elevated Mdm2 expression and concurrent p53 mutations are rarely observed.  To study 
the role of Mdm2 in vivo, two separate Mdm2 knockout mouse models were generated 
(Jones et al., 1995; Montes de Oca Luna et al., 1995).  Unlike p53-null mice, which 
undergo relatively normal development, Mdm2-null mice die post-implantation at E5.5-
6.5 of early development.  The embryos appeared much smaller than wild-type 
littermates and displayed a highly disorganized architecture.  These developmental 
defects were due to unregulated p53 activity in the embryo, as concomitant knockout of 
p53 completely rescued the early developmental lethality of Mdm2-null mice (Jones et 
al., 1995; Montes de Oca Luna et al., 1995).  These results clearly documented a critical 
role for Mdm2-dependent regulation of p53 during development.  
 
Mice deleted for both Mdm2 and p53 are viable, and form spontaneous tumors 
with a similar tissue spectrum as p53-null mice (Jones et al., 1996).  As the phenotype of 
Mdm2/p53 double-null mice and primary cells is indistinguishable from p53-null mice 
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(Jones et al., 1996), it would appear that the chief role of Mdm2 in cell growth is to act as 
a negative regulator of p53 activity.  Analysis of Mdm2 and p53 functions using 
transfection studies in human cells and murine fibroblasts generated from Mdm2/p53 
double-null embryos subsequently determined that Mdm2-p53 binding promoted the 
destabilization of p53 (Haupt et al., 1997; Kubbutat et al., 1997), providing an additional 
potential mechanism for Mdm2-mediated inhibition of p53 function.  Subsequent in vitro 
work determined that the Mdm2 protein contains a carboxy-terminal Really Interesting 
New Gene (RING) domain with E3-ubiquitin ligase activity.  Furthermore, Mdm2 was 
found to add ubiquitin moieties to p53, leading to p53 nuclear export and degradation via 
the 26S proteasome (Honda et al., 1997; Haupt et al., 1997; Kubbutat et al., 1997; Fang 
et al., 2000; Li et al., 2003).   
 
The negative regulation of p53 by Mdm2 needs to be transiently inhibited in order 
for p53 protein levels to rise and p53 downstream pathways to be activated in response to 
stress.  The mechanism that allows p53 to escape Mdm2 is not known for all cellular 
stresses, but one well-studied regulator of Mdm2 in the response to oncogene activation 
in mice is the tumor suppressor p19ARF (p14ARF in humans).  Upon activation, the p19ARF 
protein directly interacts with Mdm2, resulting in Mdm2 relocalization to the nucleolus 
(Bates et al., 1998; Kamijo et al., 1998; Pomerantz et al., 1998; Stott et al., 1998; Zhang 
et al., 1998; Honda and Yasuda, 1999; Midgley et al., 2000; Ito et al., 2001; Weber et al., 
1999).  This permits p53 protein stabilization and increased p53 function to limit the 
transformative effects of abnormal activation of cellular oncogenes (Sherr and Weber, 
2000). 
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Additional mouse models, such as the Mdm2-hypomorph (Mdm2puro), were 
generated to further explore the role of Mdm2 regulation of p53 in adult tissues 
(Mendrysa et al., 2003).  A majority of heterozygous mice bearing an Mdm2-
hypomorphic allele and an Mdm2-null allele (Mdm2puro/Δ7-9) were viable, indicating that 
the Mdm2 hypomorph protein partially retained wild-type Mdm2-dependent regulation of 
p53 during development.  However, the Mdm2-compromised, adult mice had decreased 
body weights and defects in hematopoiesis.  In agreement with a p53-dependent 
phenotype, the mice also displayed increased endogenous p53 target gene expression and 
spontaneous apoptosis.  Furthermore, Mdm2puro/Δ7-9 mice exhibited increased sensitivity 
to p53-dependent responses resulting in greatly decreased survival after whole-body 
irradiation.  This increased IR-induced lethality was shown to be solely dependent on 
p53, as Mdm2puro/Δ7-9, p53-null mice were completely radio-resistant. 
 
MdmX, a close protein family member of Mdm2, was also shown to be a critical 
regulator of p53 in vivo.  MdmX and Mdm2 share 34% amino acid identity (Figure 1.2) 
with each containing homologous p53-binding, acidic, zinc finger, and RING finger 
domains (Shvarts et al., 1996).  Like Mdm2, the MdmX gene is amplified and/or 
overexpressed in a number of different tumor types, including breast cancer, brain, soft 
tissue tumors, and retinoblastoma (Riemenschneider et al., 1999; Riemenschneider et al., 
2003; Danovi et al., 2004; Bartel et al., 2005; Laurie et al., 2006).  However, in vitro 
studies have determined that MdmX does not mediate p53 protein degradation, 
suggesting that MdmX directly inhibits p53 activity solely through steric inhibition of 
p53 transcriptional activity (Jackson and Berberich 2000; Stad et al., 2000). 
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Figure 1.2:  The domains of the Mdm2 and MdmX oncoproteins.  The percent 
identity of the individual domains shared by the two proteins are shown.  NLS: nuclear 
localization signal; NES: nuclear export signal; Zn finger: Zinc finger. 
 
 
Several groups have generated MdmX-null alleles in mice (Parant et al., 2001; 
Migliorini et al., 2002; Finch et al., 2002).  In the initial study, MdmX-null mice 
displayed an embryonic lethality at E8.5-9.5 (Parant et al., 2001), although subsequent 
MdmX-null models displayed lethality at E10.5-11.5 of gestation (Migliorini et al., 2002; 
Finch et al., 2002).  As with the Mdm2-null models, these MdmX-null mouse models can 
be rescued by co-deletion of p53.  Differences in the time of lethality between the two 
MdmX-null models may be due to subtle differences in the genetic backgrounds of the 
mice, or may arise due to slight differences in the MdmX-targeted alleles themselves. 
 
The difference in the time of lethality between Mdm2-null mice (E5.5-6) and 
MdmX-null mice (E8.5-11) indicates developmental differences in the requirements for 
Mdm2 and MdmX-mediated inhibition of p53 during development.  Furthermore, 
MdmX-null lethality in mice appears to be caused by a lack of cellular proliferation 
rather than by an increase in apoptosis (as seen in Mdm2-null embryos), and subsequent 
work has revealed that co-deletion of p21 can delay the embryonic lethality of MdmX-
null mice to E13.5-15.5 (Steinman et al., 2004).  While there is significant overlap in 
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Mdm2 and MdmX protein structure and homology, it is clear from these knockout mouse 
models that the roles and requirements of their negative regulation of p53 are notably 
different.  
 
1.5 Mdm2 and MdmX conditional knockout mice 
While the results generated from the Mdm2 and MdmX knockout studies 
demonstrated the critical roles for each in regulating p53 during gestation, the embryonic 
lethal phenotypes of these models preclude further analysis of MDM functions in latter 
stages of development or in adult tissues.  To further explore the roles of Mdm2 and 
MdmX in vivo, Mdm2 and MdmX conditional knockout mouse models have been 
generated (Steinman and Jones, 2002; Grier et al., 2002; Grier et al., 2006).  These 
models allow temporal and/or spatial-restricted ablation of MDM proteins in mice, 
circumventing the early embryonic lethality in the constitutive MDM-null models.  Using 
loxP-based conditional models and various Cre-driver mice, Mdm2 and MdmX 
expression has been subsequently ablated in many different tissue types.  A listing of 
these published studies and their results are summarized in Table 1.1. 
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Table 1.1: Published Mdm2 and MdmX tissue-specific knockout studies to date. 
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Analysis of these models has revealed major differences in the requirements of 
MDM proteins in the development of different tissue types.  For example, both Mdm2 
and MdmX are critical for development of the central nervous system (CNS) in mice 
(Xiong et al., 2006).  However, absence of both Mdm2 and MdmX in the CNS resulted in 
a more severe phenotype than either single knockout, suggesting non-overlapping effects 
in this tissue.  Conversely, deletion of Mdm2 in cardiomyocytes lead to embryonic 
lethality, whereas deletion of MdmX in these cells resulted in no obvious developmental 
defects (Grier et al., 2006).  The observations drawn from these models also suggest that 
Mdm2 and MdmX inhibit different p53-dependent responses in a tissue-specific manner.  
For example, Mdm2 clearly regulates p53-dependent apoptosis in adult intestine, 
cardiomyocytes, red blood cells, and embryonic epithelium (Valentin-Vega et al., 2008; 
Grier et al., 2006; Maetens et al., 2007; Chavez-Reyes et al., 2003).  However, in 
osteoblasts, deletion of Mdm2 results in upregulated p21 expression and a p53-dependent 
cell growth arrest, with no increase in apoptosis (Lengner et al., 2006).  Thus, the 
mechanism by which Mdm2 or MdmX regulates cell growth in a given tissue, whether by 
promoting cell proliferation or inhibiting apoptosis, is highly dependent upon the precise 
role of p53 in the biology of that specific tissue. 
 
1.6 Mdm2 and MdmX transgenic mice 
Mice bearing increased levels of Mdm2 or MdmX expression have also been 
generated to further explore MDM-p53 signaling and to model MDM gene amplification 
events frequently observed in human tumors.  Given that p53-null mice are viable, the 
Mdm2 transgenic models have been surprisingly difficult to generate.  This may be partly 
 15 
due to the unusual toxicity frequently seen in primary cells induced to overexpress Mdm2 
(Brown et al., 1998).  However, several overexpressing MDM models have been 
successfully produced and studied. The first was an Mdm2-overexpressing mouse model 
that was generated by introducing a cosmid containing the murine Mdm2 gene (including 
transcriptional start sites, introns, and 3’ sequences) into mouse embryonic stem (ES) 
cells (Jones et al., 1998).  Clones were selected that had multiple copies of Mdm2 
integrated into a single site in the genome.  These cells were used to generate chimeric 
mice, which were then bred to generate a line of Mdm2-transgenic mice that have a three 
to five fold increase in Mdm2 expression levels in various tissues.  Interestingly, ES cell 
lines exhibiting greater than 5-fold increase in Mdm2 expression proved to be incapable 
of generating even chimeric mice, suggesting that large increases in Mdm2 are 
incompatible with normal embryonic cell biology.  This is likely due to p53-independent 
effects, as p53-null ES cells are indistinguishable from wild-type ES cells and p53-null 
mice develop normally. 
 
As was seen in human cancers, overexpression of Mdm2 in mice led to 
spontaneous tumorigenesis (Jones et al., 1998).  This result indicated that overexpression 
of Mdm2 was a major contributor to tumorigenesis and not just a “passenger” event in 
human cancers.  Furthermore, the mice presented with a broad spectrum of spontaneous 
tumors similar to those seen in p53-null mice, and p53 activity and protein levels were 
diminished in tissues and cells derived from these mice.  Sequence analysis confirmed 
that the Mdm2 transgene was wild-type, revealing that Mdm2 did not require additional 
“activating” mutations to promote tumorigenesis when overexpressed.  Surprisingly, 
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Mdm2-transgenic, p53-null mice displayed a somewhat different tumor spectrum than 
p53-null mice, suggesting the existence of a p53-independent role for Mdm2 in 
tumorigenesis when overexpressed, at least in cells with inactivated p53.  The relative 
contributions of p53-dependent signaling and p53-independent mechanisms in the 
neoplastic transformation of cells that overexpress Mdm2 are important topics for future 
studies.  
 
Subsequent crosses of Mdm2-transgenic mice with MdmX+/- mice determined 
that overexpression of Mdm2 can fully rescue the embryonic lethality of the MdmX-null 
model (Steinman et al., 2005).  As it was previously established that deletion of p53 
rescues the embryonic lethality of MdmX-null mice (Parant et al., 2001; Migliorini et al., 
2002; Finch et al., 2002), the ability of the Mdm2 transgene to inhibit p53 activity in 
mice likely underlies the recovery of the Mdm2-transgenic, MdmX-null mice.  These 
results also demonstrated that MdmX is not absolutely required for Mdm2 to properly 
inhibit p53 function. 
 
Efforts to understand the role of MdmX amplification in tumorigenesis have 
produced mixed results.  One study generated a conditional MdmX transgene (MdmXTg) 
driven by the chicken β–actin promoter and CMV immediate-early enhancer (Xiong et 
al., 2010).  This conditional allele allowed temporal control over widespread MdmX 
overexpression to avoid the problems encountered in the Mdm2-transgenic model.  
However, it was determined that MdmX overexpression in this model did not lead to 
embryonic defects, and a subsequent constitutive MdmX-transgenic model (MdmXTg15) 
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was generated.  Both the MdmXTg and MdmXTg15 mice displayed increased tumorigenesis 
with a predominance of sarcomas, mirroring the tumor latency and spectrum of the 
Mdm2-transgenic model.  Because MdmX overexpression is caused by chromosome 
amplification, this study also served to verify that MdmX is an oncogene and not a 
“passenger” to other “driver” oncogene(s) on the same chromosome (Xiong et al., 2010). 
 
Interestingly, the results of a separate ROSA26-driven, Myc-tagged MdmX-
transgenic model (MdmXT) revealed a very different phenotype (De Clercq et al., 2010).  
Inheritance of one MdmX transgene (MdmXT/+) resulted in elevated MdmX levels in the 
hemizygous mice, but did not increase spontaneous, DNA damage-induced, or Eµ-Myc-
induced tumorigenesis.  This may be due to MdmX levels needing to be above a certain 
threshold to affect tumorigenesis.  However, mice homozygous for the transgene 
(MdmXT/T) die early in embryonic development and present with severe vascular defects.  
Unlike the typical lethality seen in other mouse models with varying Mdm2 and/or 
MdmX levels, the lethality in the MdmXT/T mice was completely p53-independent.  This 
may be due to the high levels of MdmX or to aspects of the transgene unrelated to MdmX 
itself.  A side-by-side comparison of the MdmX levels in the two MdmX-transgenic 
models might explain the vast differences in the phenotypes observed in these two 
studies. 
 
1.7 Mdm2 and MdmX knock-in mice: exploring RING domain function 
Mouse models have also been used to study the roles of specific Mdm2 and 
MdmX protein domains.  These models were developed as valuable tools to not only 
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confirm or refute the physiological relevance of the initial experimental results in vitro, 
but to determine whether specific domains should be favored as therapeutic targets to 
effectively manipulate p53 signaling.  As stated above, Mdm2 negatively regulates p53 
via two mechanisms: direct protein binding and E3-ligase-dependent ubiquitination.  To 
differentiate the importance of these two distinct functions, a mouse model with a 
specific knock-in mutation in the RING domain of Mdm2 (C462A) was generated 
(Itahana et al., 2007).  Co-immunoprecipitation experiments indicate that this mutation 
specifically abolished the E3-ligase activity of Mdm2 without altering the p53 binding 
function.  Surprisingly, these mice die very early in embryonic development at E7.5 in a 
p53-dependent manner.  While this proved problematic for further experimentation, the 
lethality in these mice demonstrated that binding of Mdm2-p53 is not sufficient to inhibit 
p53 activity during development.  It remains to be seen if Mdm2 E3 ligase activity is 
required for Mdm2-dependent inhibition of p53 activity at later times in development or 
in adult mice.  Although most of the phenotypes described in the various Mdm2-
conditional studies listed in Table 1.1 can be attributed to excess p53 activity in the cell, 
not all tissues ablated for Mdm2 in these studies displayed increased p53 protein levels 
(Lengner et al., 2006), and it is possible that a ligase-dead Mdm2 might still functionally 
inhibit p53 in certain tissues or in adult mice. 
 
Although MdmX and Mdm2 both contain a carboxy-terminal RING domain, 
MdmX does not appear to share the intrinsic E3 ligase activity that Mdm2 possesses for 
p53.  Rather, MdmX has been proposed to block p53 activity by binding and inhibiting 
the transactivation domain of p53 and/or by forming a heterodimer with Mdm2 and 
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promoting p53-ubiquitination indirectly by enhancing the E3 ligase activity of Mdm2 
(Shvarts et al., 1996; Stad et al., 2000; Badciong and Haas, 2002; Linares et al., 2003).  
Two mouse models with MdmX RING domain mutations have been generated to further 
explore the function of this protein domain.  One model is a conditional MdmX RING 
domain knockout in which the endogenous MdmX exon 11 was replaced with a modified 
exon 11 that is missing sequences encoding 49 amino acids from the RING domain (Pant 
et al., 2011).  Mice homozygous for the RING deletion allele (MdmXΔRING/ΔRING) did not 
develop past E9.5 due to aberrant p53 activation, so these mice were crossed to a 
conditional hypomorphic p53 model that restored wild-type p53 levels in the presence of 
Cre-recombinase.  MEFs generated from MdmXΔRING/ΔRING embryos showed that the 
MdmX RING domain was dispensable for the ubiquitination and degradation of Mdm2 
and p53, suggesting that the lethality in MdmXΔRING/ΔRING mice may be due to a lack of 
p53 transcriptional inhibition.  It is interesting to note that ablation of the MdmX RING 
domain in adult tissues had no noticeable impact on tissue function, suggesting a singular 
role for the MdmX RING domain in embryonic development. 
 
Interestingly, data from a concurrent study in which a single amino acid 
substitution was made in the endogenous murine MdmX RING domain (C462A) 
confirmed some of the results from the ΔRING model while refuting others (Huang et al., 
2011).  Mouse embryos that were homozygous for the RING domain mutation 
(MdmXC462A/C462A) were not recovered past E9.5 due to p53-dependent apoptosis and cell 
proliferation arrest, exactly replicating the embryonic lethality of the MdmXΔRING/ΔRING 
model.  Likewise, the MdmXC462A/C462A embryos displayed increased p53 target gene 
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expression that likely contributed to the embryonic lethal phenotype.  However, analysis 
of Mdm2 in MEFs generated from MdmXC462A/C462A/p53-null mice indicated that an intact 
MdmX RING domain was required for full MdmX-Mdm2 binding and Mdm2 
ubiquitination, contrary to what was seen in MEFs from the MdmXΔRING/ΔRING model.  
While it is clear that the MdmX RING domain is critical in limiting p53 activity during 
development, the precise role of the MdmX RING in p53 inhibition is still open to 
debate.  New MdmX models may be required, including those mutated for p53 
recognition but retaining the RING domain.  Such mice might be useful in resolving the 
precise contribution of the MDMX RING domain to the inhibition of p53 function. 
 
1.8 Mdm2 and MdmX knock-in mice: exploring cellular stress responses 
The above studies clearly illustrate the important roles of MDM proteins in 
inhibiting p53 activity during development and in normal tissue growth.  However, in 
order for p53 to become fully activated in response to various forms of cellular stress, 
MDM inhibition of p53 must be temporarily attenuated to facilitate p53 protein 
stabilization and subsequent target gene activation.  This rapid, transient activation of p53 
was long-thought to rely on post-translational modifications of numerous proteins within 
the p53 pathway.  These modifications might be induced by various kinases or acetyl 
transferases activated in a stress-specific manner, and would facilitate the rapid and 
specific response of cells to different types of stress.  
 
Activation of the p53 transcription factor during the DNA damage response has 
been the focus of numerous in vitro and in vivo studies, and many molecular models 
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integrating DNA damage signaling with p53 stabilization and activation have been 
proposed.  Multiple DNA damage responsive proteins recognize DNA breaks, caused by 
ionizing radiation (IR) or cytotoxic drugs, and mediate downstream pathways such as 
DNA repair and apoptosis.  The ataxia telangiectasia mutated (ATM) kinase is a major 
effector of the DNA damage response that phosphorylates a wide variety of protein 
targets.  It has been previously shown that p53 protein stabilization is dependent on 
functional ATM signaling, and p53 encodes several residues in or adjacent to the Mdm2- 
interaction domain that are known to be direct and indirect targets of ATM 
phosphorylation (Jack et al., 2002; Gurley and Kemp, 2007; Chao et al., 2000; 
MacPherson et al., 2004; Wu et al., 2002).  Several p53 knock-in mouse models have 
revealed that ATM phosphorylation of p53 is necessary for the full transcriptional 
activity of p53 after DNA damage, particularly those genes involved in apoptosis.  
However, these modifications had only modest effects on p53 protein stability and p53-
mediated tumor suppression (Sluss et al., 2004; Chao et al., 2003; Chao et al., 2006; 
Toledo and Wahl, 2006). 
 
Because activated ATM also phosphorylates Mdm2 and MdmX in vitro, it was 
proposed that ATM modification of MDM proteins might potentially regulate IR-induced 
p53 stabilization.  MdmX was proposed to be a target for DNA damage-induced 
phosphorylation by multiple kinases, including ATM (serine residue 402 in mice) and 
Chk2 (serine residues 341 and 367 in mice).  All three of these serine residues were 
mutated to alanine in a triple knock-in mouse model (MdmX3SA) to study the effect of 
DNA damage-induced phosphorylation of MdmX on p53 function (Wang et al., 2009).  
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MdmX3SA/3SA mice had impaired p53 stabilization and decreased p53 activity in response 
to IR.  Most MdmX3SA/3SA mice were radio-resistant to normally lethal doses of IR, and 
these phosphorylation events were necessary for robust suppression of lymphomas 
induced by an Eµ-Myc transgene.  However, spontaneous tumorigenesis was not 
observed in MdmX3SA/3SA knock-in mice.  Differences in the phenotypes of the Mdm2-null 
and MdmX-null mice suggest that there may be differences in the ability of Mdm2 and 
MdmX to regulate p53 activities following DNA damage.  Therefore, the contributions of 
other Mdm2 and MdmX post-translational modifications to p53 regulation and p53 tumor 
suppression following DNA damage warrant examination.  
 
1.9 Aims of this Dissertation  
This dissertation will address some of the major questions that remain in the 
Mdm2-p53 field.  Chapter 2 will illustrate the role of Mdm2 in limiting p53 activity in a 
specific tissue type in adult mice.  As described above, many tissue-specific Mdm2 
knockout mouse models have been generated, but few survive long enough to observe the 
functional consequence of unregulated p53 in adult tissues.  Ablation of Mdm2 in the 
epidermis allows the long-term study of Mdm2-p53 signaling in adult cells and permits 
stem cell functional assays to be studied while causing minimal harm to the animals.  
Chapters 3 and 4 will describe the in vivo role of a specific phosphorylation site on 
Mdm2.  In vitro studies have demonstrated that activated ATM phosphorylates MDM2 
serine residue 395, and the timing of this modification is concurrent with increased p53 
protein stability.  Generation of mouse models bearing knock-in mutations at this specific 
residue enables the necessity of this posttranslational modification to be assessed at the 
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physiological level.  These studies have contributed to the p53-Mdm2 field and open new 
scientific avenues that can be addressed in the future.      
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CHAPTER II: 
MDM2-P53 SIGNALING REGULATES EPIDERMAL STEM CELL 
SENESCENCE AND PREMATURE AGING PHENOTYPES IN 
MOUSE SKIN 
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Foreword 
The p53 transcription factor is activated by various types of cellular stress and 
induces the expression of genes that control cell growth and inhibit tumor formation.  
Analysis of mice that express mutant forms of p53 suggest that inappropriate p53 
activation can alter tissue homeostasis and life span, connecting p53 tumor suppressor 
functions with accelerated aging.  However, other mouse models that display increased 
levels of wild-type p53 in various tissues fail to corroborate a link between p53 and aging 
phenotypes, possibly due to the retention of signaling pathways that negatively regulate 
p53 activity in these models.  In this study, we have generated mice lacking Mdm2 in the 
epidermis.  Deletion of Mdm2, the chief negative regulator of p53, induced an aging 
phenotype in the skin of mice, including thinning of the epidermis, reduced wound 
healing, and a progressive loss of hair.  These phenotypes correlate with an increase in 
p53-mediated senescence and a gradual loss of epidermal stem cell numbers and 
functions.  The results of this study reveal that activation of endogenous p53 by ablation 
of Mdm2 can induce accelerated aging phenotypes in mice.  
 
Introduction 
Analysis of several p53 mouse models has suggested that p53 must be negatively 
regulated in adult mice in order to facilitate homeostatic regulation of normal tissues and 
to prevent accelerated organismal aging.  We have previously generated a mouse model 
that has one of the endogenous p53 alleles replaced with a mutant p53 allele (m) that 
encodes an amino-truncated p53 protein (Tyner et al., 2002).  This mutant p53 protein 
lacks transcription factor activity but does enhance the activity of the wild-type p53 
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protein.  In keeping with an enhanced p53 phenotype, we found that p53+/m mice display 
a significantly reduced cancer incidence relative to wild-type mice.  However, p53+/m 
mice have greatly reduced longevity due to early aging phenotypes including 
osteoporosis, reduced organ mass, a thinning of the dermis, and deficiencies in hair re-
growth and wound healing (Tyner et al., 2002).  It was proposed that the increase in p53 
activity in the p53+/m mice led to reduced stem cell proliferation in the affected tissues, 
which resulted in loss of tissue cellularity and early aging phenotypes (Tyner et al., 
2002).  More recently, the Scrable lab generated transgenic mice expressing a short, 
naturally occurring, p53 splice isoform lacking sequences encoding the amino terminal 
portion of the p53 protein.  The variant p53 protein (p44) encoded by this transgene 
induced p53 hyperactivity and a reduced cancer incidence in these transgenic mice.  The 
p44 mice displayed an increase in aging-associated insulin growth factor signaling and 
accelerated aging phenotypes, which parallels the results of the p53+/m model and 
supports a positive relationship between p53 activity and aging (Maier et al., 2004). 
 
In contrast to these findings, other mouse models that contain increased amounts 
of p53 activity fail to present with accelerated aging phenotypes.  The “super-p53” 
transgenic mice harbor an extra copy of wild-type p53 and display upregulated p53 
activities and increased cancer resistance, yet these mice have normal life span and 
normal skeletal structure, hair growth, and skin thickness (Garcia-Cao et al., 2002).  
Likewise, mice bearing reduced levels of Mdm2 activity due to the presence of a 
hypomorphic Mdm2 allele (Mdm2puro) were found to have increased levels of p53 
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activity and increased resistance to tumor formation, but did not possess any of the 
features characteristic of accelerated aging (Mendrysa et al., 2006).  
 
One possible explanation for the differences in the aging phenotypes in these 
various mouse models is that the p53 proteins encoded by the m allele and the p44 
transgene lack the amino-terminal portion of p53 containing the p53-Mdm2 interaction 
domain.  Therefore, these variant p53 proteins would not be subject to Mdm2 regulation, 
whereas Mdm2 would negatively regulate the wild-type, full-length p53 proteins encoded 
in the super p53 transgenic mice.  And although there is reduced Mdm2 function and 
increased p53 activity in the Mdm2-hypomorphic model, the endogenous wild-type p53 
proteins encoded in these mice are still subject to Mdm2 binding and regulation, albeit at 
a reduced level.  While other p53-interacting proteins may be affected, it is possible that 
the ability of Mdm2 to fully regulate p53 may underlie the presence or absence of any 
accelerated aging phenotypes in these various mouse models.   
 
An alternate explanation for the differences in aging phenotypes in these models 
is that the amino-truncated forms of p53 encoded by the m allele or the p44 transgene 
might be inducing an early aging phenotype by altering the activity of p63, a p53 family 
member that has been recently demonstrated to regulate senescence in fibroblasts and 
epithelial cells in a p53-independent manner and to induce premature aging phenotypes in 
the skin of mice (Guo et al., 2009; Flores and Blasco, 2009).  Therefore, the role of p53 
in regulating accelerated aging in mice remains a matter of much debate (Poyurovsky and 
Prives, 2006; Vijg and Hasty, 2005; Gentry and Venkatachalam, 2005). 
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In this study, we have utilized an Mdm2 conditional knockout mouse model to 
determine whether epidermal-specific loss of Mdm2-p53 signaling in newborn mice can 
induce a premature aging phenotype in the skin.  Such an approach allows us to avoid the 
embryonic lethality associated with ubiquitous or tissue-specific inactivation of Mdm2 
during development (Jones et al., 1995; Montes de Oca Luna et al., 1995; Itahana et al., 
2007; Lengner et al., 2006; Xiong et al., 2006).  Furthermore, Mdm2 does not regulate 
the stability and transcriptional activity of the p63 protein (Wang et al., 2001; Little and 
Jochemsen et al., 2001).  Therefore, ablation of Mdm2 permits a specific assessment of 
the effects of the endogenous p53 protein in organismal aging. 
 
Our results reveal that deletion of Mdm2 in mouse epidermis leads to increased 
p53 protein levels, but not p63 protein levels, and increased expression of p53 target 
genes that are specifically involved in regulating cellular senescence.  These Mdm2-
ablated mice display hallmarks of accelerated aging in their skin, including a thinning of 
the epidermal layer, reduced integrity of the skin, and widespread and progressive hair 
loss.  Analysis of the epidermis in these mice indicates increased cellular senescence in 
the follicular bulge region and a reduction in skin epidermal stem cell numbers and 
functions, as determined by FACS analysis, wound healing, and hair growth assays.  
These findings document a role for Mdm2-p53 signaling in the maintenance of the 
epidermal stem cell compartment, and demonstrate that increased activity of endogenous 
p53 can induce early aging phenotypes in mouse skin. 
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Results 
To study the role of Mdm2 in regulating p53-mediated effects on premature aging 
phenotypes, Mdm2 conditional knockout mice (Mdm2c/c) were mated with transgenic 
mice bearing the Cre recombinase (Cre) transgene under the transcriptional control of 
Keratin 5 promoter sequences (K5-Cre) (Steinman and Jones, 2002; Zhou et al., 2002).  
Since the K5 promoter is active in early postnatal development in epidermal progenitor 
cells of the skin and hair follicles, induction of Cre expression should excise exons 11 
and 12 in the conditional Mdm2 allele, resulting in loss of functional Mdm2 in the 
epidermis (Figure 2.1). 
 
 
 
Figure 2.1: The Mdm2c/c and Mdm2Δ /Δ alleles.  Exons 11 and 12 of the conditional 
Mdm2 allele (c) are flanked by loxP sites (top).  Cre recombinase deletes these floxed 
exons, generating an Mdm2 knockout allele (Δ, bottom).  Colored arrows represent PCR 
primers used to identify the conditional Mdm2 allele and to detect genomic 
rearrangement.   
 
 
To confirm robust Cre recombinase function in the epidermis of K5-Cre mice, 
Rosa26 Flox-Stop-β-Geo reporter (R26R) mice were crossed with K5-Cre mice and the 
pattern of β–galactosidase (β–gal) gene activity was examined in these compound 
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heterozygous mice.  β–galactosidase activity was detected in the interfollicular epidermis 
and hair follicles of 4-week old K5-Cre, R26R mice, indicating robust Cre recombinase 
mediated excision of floxed alleles specifically in epidermal cells (Figure 2.2).  To 
document excision of the floxed exons in the Mdm2 conditional knockout mice, genomic 
DNA was isolated from tissues of Mdm2c/c and Mdm2c/c, K5-Cre mice (Mdm2Δ/Δ), and 
PCR was performed to determine the status of the Mdm2 alleles.  Loss of functional 
Mdm2 alleles was observed in the skin of Mdm2Δ/Δ mice, but not in various control 
tissues such as spleen (Figure 2.3).  To confirm that Cre-excision of the floxed Mdm2 
exons in the epidermis resulted in loss of Mdm2 function, we examined p53 levels in the 
epidermis of Mdm2Δ/Δ mice at 5 months of age.  Western blot analysis revealed that 
endogenous p53 protein levels are slightly increased (3-4 fold by densitometry) in the 
skin of Mdm2Δ/Δ mice (Figure 2.4). 
  
 
 
Figure 2.2: LacZ staining in Rosa26 Flox-Stop β-Geo reporter mice expressing the 
K5-Cre transgene.  Scale bar represents 100 µm. 
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Figure 2.3: PCR indicates excision in the skin of Mdm2Δ /Δ mice.  Genomic PCR 
indicates excision of the Mdm2 allele specifically in the skin of Mdm2c/c mice that also 
inherited the K5-Cre transgene.  Colored arrows correspond to the primers in Figure 2.1.  
Gapdh was used as a loading control.   
 
 
 
Figure 2.4: Western blot of p53 protein levels in skin from 5-month-old mice.  α-
Tubulin was used as a loading control. 
 
 
Loss of Mdm2 function has been associated with an increase in p53-mediated cell 
growth arrest or apoptosis in a number of mouse models, resulting in aberrant tissue 
function (Jones et al., 1995; Montes de Oca Luna et al., 1995; Itahana et al., 2007; 
Mendrysa et al., 2006; Lengner et al., 2006; Xiong et al., 2006; Grier et al., 2006).  
Surprisingly, Mdm2Δ/Δ mice younger than 10 months of age display no overt phenotype, 
despite the loss of Mdm2 function and increased p53 stabilization in the epidermis 
(Figures 2.5 and 2.6).   
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Figure 2.5: Younger Mdm2c/c (left) and Mdm2Δ /Δ mice (right) reveals no overt 
phenotypic difference.   
 
 
 
 
Figure 2.6: H&E staining of representative hair follicles from young Mdm2c/c (left) 
and Mdm2Δ /Δ mice (right).  Scale bars represent 100 µm. 
 
 
However, all Mdm2Δ/Δ mice displayed progressive hair loss and decreased skin 
elasticity as they continued to age (Figure 2.7).  Analysis of hematoxylin & eosin (H&E) 
-stained sections of skin from older (14-15 month old) Mdm2Δ/Δ mice revealed fewer hair 
follicles per millimeter (fl/mm) of dorsal skin in Mdm2Δ/Δ mice (0.70 fl/mm) than in 
 33 
control Mdm2c/c mice (1.4 fl/mm) (p=0.003).  In addition, 27.1% of Mdm2Δ/Δ follicles 
display an abnormal phenotype compared to 7.0% of the follicles in age-matched 
Mdm2c/c controls (p=0.004).  These abnormal Mdm2Δ/Δ follicles were dilated, debris-
laden, devoid of a hair shaft, cellularly atrophic, and morphologically disorganized 
(Figure 2.8).  
 
 
 
 
Figure 2.7: Phenotype of older Mdm2Δ /Δ mice (right).  These include increased hair 
loss in aged mice deleted for Mdm2 compared to older Mdm2c/c mice (left). 
 
 
 
 
 
Figure 2.8: H&E staining of representative hair follicles from older Mdm2c/c (left) 
and Mdm2Δ /Δ mice (right).  Scale bars represent 100 µm.   
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In addition to defects in hair maintenance, approximately 10% of all Mdm2Δ/Δ 
mice developed severe open skin wounds between 18-24 months of age.  As these 
affected mice were housed individually, the skin lesions were likely caused by self-
grooming.  Similar wounding was not observed in age-matched, Mdm2c/c control mice or 
in older K5-Cre transgenic mice.  To further examine the epidermal defects in these mice, 
skin biopsies were taken from Mdm2Δ/Δ mice and Mdm2c/c control mice at 16 months of 
age.  There was an obvious decrease in the thickness of the interfollicular epidermis in 
older Mdm2Δ/Δ mouse relative to age-matched controls, accounting for the diminished 
integrity of the epidermal layer in older Mdm2Δ/Δ mice (Figure 2.9).  These phenotypes 
are not present in young Mdm2Δ/Δ mice (Figure 2.6), suggesting a gradual degeneration 
of epidermal skin and hair follicle morphology in Mdm2Δ/Δ mice over time. 
 
 
 
Figure 2.9: H&E staining of interfollicular epidermis from older Mdm2c/c (left) and 
Mdm2Δ /Δ mice (right).  Scale bars represent 100 µm.   
 
 
To examine epidermal p53 levels in older mice, we performed western blot 
analysis using skin protein lysates isolated from 20- to 23-month old Mdm2Δ/Δ and 
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Mdm2c/c mice, as well as lysates isolated from γ–irradiated (3Gy) control mice (Figure 
2.10).  The amount of p53 present in older Mdm2Δ/Δ skin was far greater than the level of 
p53 detected in age-matched control Mdm2c/c skin, and was comparable to p53 levels 
observed in irradiated Mdm2c/c controls.   
 
 
 
Figure 2.10: Western blot of p53 protein levels in skin from untreated and γ-
irradiated (3Gy, 15 hours) 20- to 23-month-old mice.  α-Tubulin was used as a loading 
control.   
 
 
To determine if the highly elevated p53 levels in older Mdm2Δ/Δ mice correlated 
with increased p53 activity, we examined the expression levels of select p53 target genes 
in the skin of 5-month old mice and 16-month old mice by quantitative real-time PCR 
(qRT-PCR) (Figure 2.11).  Little or no elevation of the expression levels of p53 target 
genes was observed in the younger mouse skin (left panel).  In contrast, the large increase 
in p53 protein levels in the older mouse skin correlated with an increase in p53 target 
gene activation (right panel).  However, only a subset of p53 target genes displayed 
increased expression in older Mdm2Δ/Δ skin samples.  Interestingly, these upregulated 
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p53 targets included genes associated with cell cycle arrest and senescence (p21, Pai-1 
and Pai-2) but not apoptosis (Puma and Noxa).  
 
 
 
Figure 2.11: Relative mRNA levels of p53 target genes in untreated skin from young 
(left) and older (right) mice determined by qRT-PCR.  Values represent the fold 
difference in Mdm2Δ/Δ mice compared to Mdm2c/c mice (n=3 per genotype).  All levels 
were normalized to Gapdh.  Standard deviation indicated by error bars. 
  
 
To confirm that ablation of Mdm2 and upregulation of p53 activity in the skin of 
Mdm2Δ/Δ mice did not induce apoptosis in this tissue, we performed terminal 
deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) staining on skin sections 
of 14-16 month old Mdm2Δ/Δ and Mdm2c/c mice (Figure 2.12).  TUNEL staining was 
readily detected at the base of those follicles undergoing remodeling (catagen-phase).  
This staining was anticipated, because normal hair remodeling is ongoing even in older 
mice and appears to be regulated primarily by Bcl2 and not by p53 (Stenn and Paus, 
2001).  However, TUNEL positive cells were not observed in either the follicular or 
interfollicular epidermis of older Mdm2c/c or Mdm2Δ/Δ mice indicating that increased p53 
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activity in the skin of Mdm2Δ/Δ mice did not correlate with an increased number of 
apoptotic cells (note the lack of any cellular staining in the figures).  These negative 
results correlate with the lack of increased apoptotic gene expression seen in the skin of 
Mdm2Δ/Δ mice, confirming that the loss of hair and thinning of the epidermis seen in the 
Mdm2Δ/Δ mice is unlikely to be due to p53-mediated apoptosis in the skin. 
 
 
 
Figure 2.12: TUNEL staining of skins from aged Mdm2c/c and Mdm2Δ /Δ mice.  Scale 
bars represent 100 µm.   
 
 
Increased cellular senescence has been linked to aging phenotypes in other mouse 
models (Rodier et al., 2007).  Since upregulation of p53 activity in Mdm2Δ/Δ mice 
resulted in the activation of p53 target genes primarily involved in cell senescence, we 
examined the epidermis of older Mdm2Δ/Δ mice for senescent cells.  Skin sections of 16-
month old Mdm2Δ/Δ mice and Mdm2c/c mice were fixed and stained for senescence-
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associated-β–galactosidase (SA-β-Gal) activity.  SA-β-Gal activity was undetectable in 
the follicular epithelium of Mdm2c/c control mice, whereas 21% (±3.6%) of the hair 
follicles in Mdm2Δ/Δ mice stained positive for SA-β-Gal activity (Figure 2.13).  
Interestingly, SA-β-Gal staining was particularly acute in the follicular bulge, the region 
of the follicle containing the epidermal stem cell compartment (Tumbar et al., 2004).   
 
 
 
Figure 2.13: Senescence-associated-β-galactosidase activity detected in skin of aged 
Mdm2Δ /Δ mice (top) but not in Mdm2c/c mice (bottom).  Sections were counterstained 
with Nuclear Fast Red.  Scale bars represent 50 µm.  Arrowheads denote SA-β-gal stain. 
 
 
To confirm senescence of epidermal cells in Mdm2Δ/Δ mice, we examined 
expression of the p16INK4A tumor suppressor, a gene whose expression is not governed by 
p53 and that has been previously reported to be increased in senescent and aging skin 
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cells of older mice and humans (Jenkins, 2002; Ressler et al., 2006; Campisi, 2005).  A 
significant increase in p16INK4A expression was detected by qRT-PCR in the skin of older 
Mdm2Δ/Δ mice, relative to expression levels in age-matched Mdm2c/c skin (Figure 2.14), 
confirming that loss of Mdm2-p53 signaling induces an established molecular marker of 
senescence and accelerated aging in the epidermis.   
 
 
 
Figure 2.14: Relative p16INK4A mRNA levels in skin from older mice determined by 
qRT-PCR (n=3 per genotype).  Levels were normalized to Gapdh.  Standard deviation 
indicated by error bars. 
 
 
SA-β-Gal staining of the follicular bulge region and upregulation of p16INK4A 
expression indicates premature cell senescence in the epidermal stem cell compartment of 
Mdm2Δ/Δ mice.  To confirm that the defect in Mdm2Δ/Δ mice is due to the reduced 
numbers of epidermal stem cells, we examined Mdm2Δ/Δ follicular bulge cells for 
cytokeratin 15 (K15) and LIM homeobox protein 2 (Lhx2) staining, specific markers of 
bulge stem cells in mice (Liu et al., 2003; Rhee et al., 2006).  Staining of skin cross 
sections of older Mdm2Δ/Δ and control Mdm2c/c mice revealed a decrease in K15-positive 
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and Lhx2-positive cells in Mdm2Δ/Δ mice (Figure 2.15).  Typical follicles in Mdm2Δ/Δ 
mice have very faint K15 and Lhx2 staining compared to age-matched control follicles, 
and staining is absent in the all of the abnormal follicles examined in Mdm2Δ/Δ mice.  
 
 
 
Figure 2.15: Follicular cytokeratin 15 (left) and Lhx2 (right) staining in older 
Mdm2c/c and Mdm2Δ /Δ mice.  Arrowheads denote specific staining.  Scale bars 
represent 25 µm. 
  
 
To confirm a reduction in numbers of epidermal stem cells in mice ablated for 
Mdm2, we performed FACS analysis of epidermal cells harvested from age-matched 
Mdm2Δ/Δ and control Mdm2c/c mice and documented the numbers of cells expressing 
high levels of both CD34 and a6-integrin, well-established epidermal stem cells markers 
(Nowak and Fuchs, 2009).  In agreement with our K15 and Lhx2 staining results, fewer 
CD34/a6-intgrin double-positive cells are present in the skin of Mdm2Δ/Δ mice compared 
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to the numbers of double positive cells in Mdm2c/c control mice (Figure 2.16).  
Interestingly, while fewer epidermal stem cells are seen in the skin of Mdm2Δ/Δ mice at 3 
months and 9 months of age (before the skin phenotype is observed in these mice), a 
much larger decrease in epidermal stem cell numbers is seen in 14-month old Mdm2Δ/Δ 
mice (Figure 2.16), when the phenotype of the Mdm2Δ/Δ mice is readily apparent (see 
Figure 2.7 and 2.8). 
 
 
 
Figure 2.16: Quantification of bulge stem cells by FACS.  Representative FACS plots 
for 9-month-old Mdm2c/c and Mdm2Δ/Δ mice (left).  Bulge stem cells (CD34high/α6-
Integrinhigh) are shown in black boxes.  The total percentages of CD34high/α6-Integrinhigh 
cells determined by FACS analysis in Mdm2c/c (grey bars) and Mdm2Δ/Δ (white bars) 
mice are plotted at right (n=3 per genotype).  Standard deviation indicated by error bars.    
 
 
Loss of tissue regenerative potential and disrupted organ homeostasis are 
hallmarks of normal aging in mice and are often exacerbated in mouse models of 
accelerated aging (Rodier et al., 2007; Campisi, 2005).  In skin, follicular bulge stem 
cells produce transiently amplifying epidermal progenitor cells that migrate to wounded 
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areas of the interfollicular epidermis and coordinate the wound healing response (Tumbar 
et al., 2004; Taylor et al., 2000).  To confirm that epidermal stem cell function is 
compromised in older Mdm2Δ/Δ mice, we compared the decrease in diameter of an 
introduced 3mm2 dorsal wound in Mdm2Δ/Δ mice and Mdm2c/c control mice.  Wounds in 
younger (2 to 4-month old) Mdm2Δ/Δ and Mdm2c/c mice healed at a similar rate (Figure 
2.17), with an average 65% wound closure in mice of both genotypes at 8 days.  Wounds 
in older (14 to 16-month old) Mdm2c/c control mice closed at a rate similar to that seen in 
the younger mice.  In contrast, wounds in the older Mdm2Δ/Δ mice closed at a much 
slower rate, consistent with a decrease in epidermal stem cell function.  After 8 days, the 
wound sites in control Mdm2c/c mice were fully healed, whereas the wound sites in age-
matched Mdm2Δ/Δ mice remained mostly open (Figure 2.17).  
 
Epidermal stem cells are also required to promote the anagen-telogen-catagen hair 
cycle (Tumbar et al., 2004; Morris and Potten, 1999), and the rate of hair regrowth after 
shaving of mice is another direct measure of follicular stem cell function.  To further 
confirm loss of epidermal stem cell-mediated functions in older Mdm2Δ/Δ mice, we 
shaved the hair from a 4cm2 dorsal area on Mdm2Δ/Δ mice and Mdm2c/c control mice and 
measured hair re-growth over time (Figure 2.18).  Parallel to the wound healing results, 
hair growth in older (14-16 month old) Mdm2Δ/Δ mice is significantly delayed relative to 
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control mice in the 3-week interval after shaving (Figure 2.18).  In addition, older 
Mdm2Δ/Δ mice display reduced hair growth even 80 days post-shaving (Figure 2.18). 
 
 
 
 
Figure 2.17: Wound healing assay of 2- to 4-month old and 14- to 16-month old 
Mdm2c/c (grey bars) and Mdm2Δ /Δ mice (white bars).  The decrease in diameter of a 
dorsal punch biopsy wound was measured over time (n=3 per genotype).  Standard 
deviation indicated by error bars.  H&E staining of wounds (bottom) from a Mdm2c/c 
mouse and a Mdm2Δ/Δ mouse at day 8 of the wound healing assay.  Scale bars represent 
250 µm.   
 
 
Discussion 
The Mdm2Δ/Δ mice present a premature aging phenotype in the epidermis that is 
highly similar to the accelerated aging phenotype that we observed previously in the skin  
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Figure 2.18: Hair re-growth in 16- to 20-month-old mice.  The percentage hair growth 
for Mdm2c/c mice (solid line) and Mdm2Δ/Δ mice (dotted line) was plotted over time (n=3 
per genotype).  Standard deviation indicated by error bars.  Pictures of an aged Mdm2c/c 
mouse and Mdm2Δ/Δ mouse at day 1 and day 80 post-shaving (right). 
 
 
of p53+/m mice, including a thinning of the epidermal layer, reduced wound healing, and a 
reduced capacity to re-grow hair.  As deletion of Mdm2 results in an increase in 
endogenous p53 levels, but no detectable change in p63 protein levels (Figure 2.19), and 
upregulation of select p53 target gene expression in the epidermis of Mdm2Δ/Δ mice, our 
results corroborate that an increase in p53 activity in p53+/m mice is responsible for the 
accelerated aging phenotypes observed previously in this model and in certain other p53 
models (Tyner et al., 2002; Maier et al., 2004).  However, not all mouse models bearing 
increased levels of p53 display premature aging, and retention of some degree of Mdm2-
p53 signaling in these models may well account for the lack of accelerated aging-like 
phenotypes in these mice (Garcia-Cao et al., 2002; Mendrysa et al., 2006). 
 
It is interesting to note that ablation of Mdm2 and upregulation of p53 in the 
epidermis did not result in p53 activation of pro-apoptotic genes and immediate cell death 
as seen in other settings (Lengner et al., 2006; Xiong et al., 2006; Martins et al., 2006).   
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Figure 2.19: Western blot of p63 protein levels in skin from older mice.  The multiple 
isoforms of p63 resulted in multiple bands on the western blot.  α-Tubulin was used as a 
loading control.   
 
 
This may be due to epigenetic networks of histone modifications that have recently been 
found to exist in epidermal stem cells (Mulder et al., 2012).  Disruption of Mdm2-p53 
signaling induced SA-β-Gal staining of the follicular bulge region, indicating cellular 
senescence within the epidermal stem cell compartment in Mdm2Δ/Δ mice.   Thus, the 
ability of Mdm2 to properly regulate p53-mediated senescence in this tissue determines 
the presence or absence of p53-associated aging phenotypes.  Activation of p53-mediated 
cell senescence in epidermal stem cells and altered wound healing has also been observed 
in mice bearing shortened telomeres (Flores and Blasco, 2009), supporting a role for p53 
activation in regulating epidermal stem cell function.  However, as hair loss and reduced 
skin integrity was not reported in these mice, the differences in the level of p53 activation 
or the timing of p53-induced senescence in the epidermis may also underlie the presence 
or absence of aging-like phenotypes in the skin. 
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The results of our study reveal that loss of Mdm2, the concomitant upregulation 
of p53, and the subsequent induction of p53-mediated senescence induces an accelerated 
aging (but not progeria-like) phenotype in the skin.  Although increased p53 levels can be 
detected in the skin of younger Mdm2Δ/Δ mice (Figure 2.4), these mice do not display 
upregulated levels of p53-target genes in their skin (Figure 2.11), and the Mdm2Δ/Δ mice 
appear unaffected up to 10 months (Figures 2.5 and 2.6).  However, after 10 months of 
age hair loss and epidermal thinning becomes readily apparent in these mice.  As stem 
cells in the epidermal bulge region are generated during late embryogenesis in the mouse 
(Stenn and Paus, 2001), the postnatal ablation of Mdm2 induced by Cre recombinase in 
our model may be governing epidermal stem cell renewal and not the functional 
differentiation of pre-existing epidermal stem cells and their subsequent progenitors.  In 
keeping with this possibility, it has been established previously that follicle bulge cells 
are slow cycling, with an average of 14 months in the mouse (Morris and Potten, 1999).  
Thus, the pre-established epidermal stem cell compartment in Mdm2Δ/Δ mice likely 
retains cells that are still capable of differentiating into committed progenitor cells that 
form the follicular and inter-follicular epidermis, but have lost the capacity to self-renew 
the epidermal stem cell compartment, leading to exhaustion of the stem cell population 
with age.  
 
An alternate possibility of the late developing phenotype seen in the Mdm2Δ/Δ 
mice is that the epidermal stem cell niche is being affected by the loss of Mdm2 and is 
indirectly impacting epidermal stem cell function.  Most of the experiments presented 
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studied a mixed population of epidermal and dermal cells from whole skin extracts.  
Further isolation of the various cells of the epidermis would uncover many characteristics 
of the epidermal stem cells from Mdm2Δ/Δ mice such as direct genomic rearrangement of 
the Mdm2 locus and whether these cells are undergoing senescence via known markers 
and expression changes in p21, Pai-1, and Pai-2.  These studies could decipher between 
these two hypotheses regarding why the phenotypes do not present before 10 months and 
may reveal additional possibilities.   
 
Furthermore, the precise role of p53-induced senescence in regulating epidermal 
stem cell self-renewal or the epidermal stem cell niche will be a matter for further 
investigation.  The role of Mdm2 loss leading to increased p16INK4A expression is also an 
interesting avenue for discovery to determine whether senescence in one cell (due to p53) 
could have paracrine effects on surrounding cells (due to increased p16INK4A) to 
perpetuate the senescence response within the stem cell niche.  Additional Mdm2 (and 
perhaps MdmX) deletion models in different cell types may further elucidate this role. 
 
Our findings reveal that activation of p53 due to loss of Mdm2 in the skin of 
Mdm2 conditional knockout mice induces p53-mediated senescence within the epidermal 
stem cell compartment and a reduction in epidermal stem cell percentage, overall 
numbers, and functions in older mice.  In addition, Mdm2-mediated inhibition of p53 
activity in epithelial cells of the skin is essential for maintenance of skin integrity and 
hair as mice age. Thus, Mdm2-p53 signaling governs certain rapid-aging phenotypes in 
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skin.  The ability of Mdm2 to properly downregulate p53 in other p53 mouse models may 
therefore account for the presence or absence of aging-like phenotypes in these models. 
 
Materials and Methods 
Mice and Genotyping 
The generation of both the Mdm2 conditional knockout mice (Steinman and Jones, 2002) 
and the K5-Cre transgenic mice (Zhou et al., 2002) has been described previously.  
Rosa26 Flox-Stop-β-Geo reporter mice (Stock#: 003310) were obtained from Jackson 
Laboratories. All experimental and littermate control mice used in this study were on a 
mixed 129Sv X C57Bl/6 background.  Genomic PCR was used to identify inheritance of 
the K5-Cre transgene (primers 5’-CGGTCGATGCAACGAGTGAT-3’ and 5’-
CCACCGTCAGTACGTGAGAT-3’), to identify inheritance of the conditional Mdm2 
allele (primers 5’-GGTCTTCCCATTTATGTATGT-3’ and 5’-
AAGAGTCTGTATCGCTTTCT-3’), and to verify Mdm2 allelic excision (primers 5’-
GGTCTTCCCATTTATGTATGT-3’ and 5’-TCCACCTCTTTCTTCTTCCTG-3’).  
Animals were maintained and used in accordance with federal guidelines and those 
established by the Institutional Animal Care and Use Committee at the University of 
Massachusetts Medical School. 
 
Western Blotting and Reagents 
Protein lysates were collected using a modified protocol described previously 
(Balasubramanian et al., 1998).  A 10mm2 dorsal section of skin tissue was homogenized 
in 1 ml NP-40 lysis buffer [50 mM Tris-HCl, pH 7.5; 150 mM NaCl; 0.5% NP-40; 20% 
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Glycerol; 1X protease inhibitor cocktail (Roche); 1X phosphatase inhibitor cocktail 
(Roche)].  Samples were placed on ice for 15 minutes, vortexed, and centrifuged at 13000 
rpm for 20 minutes.  Supernatants were collected, and 50 µg of each sample loaded onto 
a 10% SDS-polyacrylamide gel.  Antibodies against p53 (1:500 of both Ab-1 and Ab-3 
from Calbiochem), p63 (1:500 H-137, sc-8343 from Santa Cruz), and α-tubulin (1:4000 
T5168 from Sigma) were diluted in 5% non-fat milk.   
 
Gene Expression Analysis 
Total mRNA from skin tissue was isolated according to the Trizol Reagent (Invitrogen) 
protocol, and cDNA was generated using the SuperScript II First Strand Synthesis Kit 
(Invitrogen).  The following primers were used in real time PCR reactions to determine 
relative gene expression:  
p21: 5’-TGAGGAGGAGCATGAATGGAGACA-3’ and  
5’-AACAGGTCGGACATCACCAGGATT-3’, 
Pai-1: 5’-GCTGCACCCTTTGAGAAAGA-3’ and  
5’-GCCAGGGTTGCACTAAACAT-3’,  
Pai-2: 5’-GGGCTTTATCCTTTCCGTGT-3’ and  
5’-GTGTGTCTTTGCTGATCCAC-3’, 
Puma: 5’-CCTGGAGGGTCATGTACAATCT-3’ and 
5’-TGCTACATGGTGCAGAAAAAGT-3’, 
Noxa: 5’-CCACCTGAGTTCGCAGCTCAA-3’ and  
5’-GTTGAGCACACTCGTCCTTCAA-3’,  
p16INK4A: 5’-ATCTGGAGCAGCATGGAGTC-3’ and  
 50 
5’-TCGAATCTGCACCGTAGTTG-3’,  
Gapdh: 5’-TGGCAAAGTGGAGATTGTTGCC-3’ and  
5’-AAGATGGTGATGGGCTTCCCG-3’.  
  
Histology 
Skin tissue was fixed in 10% formalin overnight.  Skin sections (5µm) were stained with 
hematoxylin and eosin (H&E), anti-cytokeratin 15 (K15) antibody from Neomarkers 
(Freemont, CA), or anti-Lhx2 from Santa Cruz (sc-19342) as performed by the UMMS 
DERC Morphology Core.  TUNEL staining of tissue sections to detect apoptotic cells 
was performed using the In Situ Cell Death Detection Kit, POD (Roche, 11684817910). 
 
Senescence-Associated-β-Galactosidase Staining 
Fresh skin tissue was washed twice with PBS, followed by briefly fixing in 2% 
formaldehyde/0.2% glutaraldehyde for 5 minutes.  The tissue was rinsed twice in PBS 
and then completely submerged in staining solution [all diluted in 40 mM citrate/sodium 
phosphate buffer (pH 6): 5 mM potassium ferricyanide; 5 mM potassium ferrocyanide; 2 
mM MgCl2; 150 mM NaCl; 1mg/ml X-gal] for 4 hours in the dark at 37 °C.  After two 
washes with PBS, the tissue was fixed overnight in 10% formalin and paraffin embedded.  
Sections were counterstained with either H&E or Nuclear Fast Red. 
 
Isolation of Bulge Stem Cells 
Epidermal bulge stem cells were isolated according to a previous protocol (Nowak and 
Fuchs, 2009).  Whole skin was treated with 0.25% trypsin overnight, which allowed 
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complete segregation of the epidermis from the dermis.  The resulting epidermal cell 
suspensions were washed with media, resuspended in staining buffer (2% fetal bovine 
serum in sterile PBS), and stained with the following antibodies: phycoerythrin-
conjugated rat anti-human CD49f [integrin α6 chain] (clone GoH3) from BD 
Pharmingen; biotin-conjugated rat anti-mouse CD34 (clone RAM34) from eBioscience; 
strepavidin-allophycocyanin conjugate from BD Pharmingen).  Cells were stained with 7-
aminoactinomycin D (7-AAD, Cat. No. 00-6993-50) from eBioscience to determine cell 
viability.  FACS was performed by the UMASS Medical School Flow Cytometry Core 
Facility.       
 
Wound Healing Assay  
The wound healing procedure was modified from a previously described protocol (Tyner 
et al., 2002).  The dorsal surface of anesthetized mice (0.023 cc/gram body weight, 1.2% 
Avertin) was completely shaved with an electric razor and disinfected with Betadine 
(Cardinal Health) and 75% ethanol.  A 3mm punch biopsy was used to introduce a single 
wound on the dorsum of each mouse.  The wounds were imaged each day and the 
diameter of each wound was measured.  Healing was defined as the decrease in wound 
diameter over time, and was expressed as the percentage of the day 0 wound diameter.   
 
Hair Growth Assay 
The procedure for this assay was modified from a previously described protocol (Tyner et 
al., 2002).  A 2cm2 dorsal section of skin on age-matched mice was shaved with an 
electric razor at day 0.  A 0.5cm2 square grid was used to measure hair re-growth, which 
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was defined as the percentage of the total number of squares that are covered with over 
50% new hair.  Measurements were taken every 3-4 days.  
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CHAPTER III: 
ATM PHOSPHORYLATION OF MDM2 SER394 REGULATES THE 
AMPLITUDE AND DURATION OF THE DNA DAMAGE 
RESPONSE IN MICE 
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Foreword 
DNA damage induced by ionizing radiation (IR) activates the ATM kinase, which 
subsequently stabilizes and activates the p53 tumor suppressor protein.  Although 
phosphorylation of p53 by ATM was found previously to modulate p53 levels and 
transcriptional activities in vivo, it does not appear to be a major regulator of p53 
stability.  We have utilized mice bearing altered Mdm2 alleles to demonstrate that ATM 
phosphorylation of Mdm2 serine 394 is required for robust p53 stabilization and 
activation after DNA damage.  In addition, we demonstrate that dephosphorylation of 
Mdm2 Ser394 regulates attenuation of the p53-mediated response to DNA damage.  
Therefore, the phosphorylation status of Mdm2 Ser394 governs p53 protein levels and 
functions in cells undergoing DNA damage. 
 
Introduction 
The p53 tumor suppressor has been called the “guardian of the genome” due to its 
ability to prevent genotoxic insults from inducing heritable alterations in damaged cells 
(Lane, 1992).  In response to cellular stresses such as DNA double-strand breaks, 
hypoxia, and inappropriate oncogene activation, the p53 transcription factor is stabilized 
within the cell and induces the expression of various p53 target genes involved in cell 
cycle arrest, apoptosis, and senescence (Vousden and Lu, 2002).  These p53-dependent 
effector pathways regulate the proliferation and propagation of damaged cells to limit 
cellular transformation and tumorigenesis, and mice deleted for p53 rapidly develop 
thymic lymphomas, sarcomas and other tumor types (Donehower et al., 1992).  
Additionally, over 50% of all human tumors harbor p53 mutations (Soussi and Beroud, 
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2001; Hollstein et al., 1991).  These findings clearly demonstrate the necessity of 
functional p53 signaling in suppressing tumorigenesis. 
 
DNA damage induced by ionizing radiation is a well-established initiator of p53 
activity.  Wild-type (WT) mice that are treated with whole body IR undergo p53-
dependent apoptosis in both radiosensitive tissues such as thymus, spleen, and small 
intestine, and in hematopoietic cells (Gudkov and Komarova, 2003).  Mice exposed to 8 
Grays (Gy) or more of IR will die within 3 weeks due to depletion of the hematopoietic 
compartment, a condition known as hematopoietic syndrome (Komarova et al., 2004).  In 
contrast, p53-null mice are more tolerant of acute radiation, as their hematopoietic cells 
are less prone to IR-induced apoptosis.  However, p53-deficient mice display an 
increased rate of tumorigenesis following IR treatment (Kemp et al., 1994).         
 
Activation of p53 in response to DNA damage necessitates a transient attenuation 
of Mdm2-dependent p53 inhibition.  Post-translational modifications of the p53 protein 
by DNA damage-inducible kinases, specifically ATM, were initially thought to inhibit 
the interaction of p53 and Mdm2 (Shieh et al., 1997).  Atm-null mice do not survive past 
6 months of age due to the increase in T-cell lymphomagenesis, demonstrating a key role 
for ATM in tumor suppression (Barlow et al., 1996; Elson et al., 1996; Xu and 
Baltimore, 1996; Herzog et al., 1998).  Experiments utilizing the cells of these Atm-null 
mice demonstrated the necessity of ATM signaling in p53 stabilization in mouse 
embryonic fibroblasts (MEFs) and murine thymus following IR (Jack et al., 2002; Gurley 
and Kemp, 2007).  ATM directly and indirectly (via Chk2) phosphorylates p53 on Ser18 
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and Ser23 in irradiated mice (Ser15 and Ser20 on human p53) (Chao et al., 2000; Wu et 
al., 2002).  These serine residues are located within or adjacent to the Mdm2 binding 
domain of p53, and initial in vitro studies demonstrated that phosphorylation of p53 
decreased the p53-Mdm2 interaction in transfection and overexpression experiments 
(Shieh et al., 1997).  Several groups, including our own, subsequently generated mouse 
models bearing modified p53 alleles to examine the role of these post-translational 
modifications in p53 regulation and function in vivo (Chao et al., 2003; Sluss et al., 2004; 
Chao et al., 2006).  These studies revealed that phosphorylation of these ATM-target 
serines on p53 modulated the transcriptional activity of p53, but had only a moderate 
effect on DNA damage-induced stabilization of the p53 protein.  
 
In addition to modifying p53, transfection-based assays have revealed that ATM 
can directly phosphorylate serine 395 of human MDM2 (Khosravi et al., 1999; Maya et 
al., 2001).  This suggested for the first time that p53 stabilization after DNA damage 
could be due to posttranslational modifications on Mdm2.  One study utilized an MDM2 
expression construct with the serine residue 395 codon replaced by sequences encoding 
aspartic acid (S395D), thus mimicking a constitutively phosphorylated serine residue.  
The MDM2 S395D protein exhibited a decreased capacity to induce p53 degradation and 
nuclear export, suggesting that phosphorylation of MDM2 Ser395 altered p53 activation 
following DNA damage (Maya et al., 2001).  Further in vitro work suggested that ATM 
phosphorylation of multiple amino acid residues on MDM2, including Ser395, inhibited 
both MDM2 RING domain oligomerization and E3 ligase activity (Cheng et al., 2009; 
Cheng et al., 2011).  Interestingly, recent work has indicated that ATM phosphorylation 
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of MDM2 switches MDM2 from a negative to a positive regulator of p53, as 
phosphorylation of MDM2 Ser395 increased the interaction between Mdm2 protein and 
p53 mRNA and led to increased p53 translation (Gajjar et al., 2012).  These transfection-
based studies suggest that the ATM-dependent induction of the p53 protein is mediated 
by ATM phosphorylation of MDM2.         
 
In keeping with a role for MDM2 Ser395 phosphorylation in the p53 DNA 
damage response, we have previously shown that the wild type p53-induced phosphatase 
1 (Wip1) oncoprotein can dephosphorylate MDM2 Ser395 in vitro (Lu et al., 2007).  
Multiple in vitro studies have shown that Wip1 dephosphorylates, and thus inactivates, 
proteins that are activated by ATM including Chk1, p53 (Lu1 et al., 2005), Chk2 (Olivia-
Trastoy et al., 2007), and even ATM itself (Shreeram et al., 2006a).  Therefore, Wip1 has 
been proposed to reset DNA damage signaling to pre-stress levels following resolution of 
the DNA damage response (Lu et al., 2008).  Overexpression of Wip1 has been shown to 
inhibit the normal IR-induced p53 response in vitro (Lu et al., 2007), and Wip1-null mice 
and MEFs have growth kinetics, cell cycle defects, p53 target gene expression, and 
delayed tumorigenesis indicative of a prolonged p53 response (Choi et al., 2002; 
Nannenga et al., 2006).  As its name suggests, the Wip1 gene is a transcriptional target of 
p53, so that, like Mdm2, p53 activation quickly induces its own negative regulators to 
ensure tight control (Fiscella et al., 1997). Although the coincidental timing of MDM2 
Ser395 phosphorylation and dephosphorylation suggests that this modification may 
coordinate the p53-dependent response to DNA damage, the in vivo functional 
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significance of MDM2 phosphorylation in Mdm2-p53 regulation, p53 activation, and in 
tumorigenesis remains unknown. 
 
To determine the role of MDM2 Ser395 phosphorylation in p53 regulation under 
physiological settings, we have generated two knock-in mouse models bearing Mdm2 
Ser394 substitutions (the orthologous human Ser395 residue in the mouse).  Our results 
generated from these two models reveal that Mdm2 Ser394 phosphorylation is necessary 
for DNA damage-induced p53 stabilization in hematopoietic tissues and primary cells 
and is a critical regulator of p53-mediated apoptosis, growth arrest, and tumor 
suppression.  Additionally, Mdm2 Ser394 phosphorylation impacts the duration of the 
p53 response to DNA damage. 
 
Results 
To investigate the role of Mdm2 Ser394 phosphorylation under physiological 
conditions, we generated a mouse model in which this serine residue is substituted with 
an alanine residue (A394).  This model produces a mutant Mdm2 protein with a 
conserved native structure that cannot be phosphorylated at position 394.  Site-directed 
mutagenesis was performed to introduce missense mutations within the 394 codon of 
Mdm2 exon 12 (Figure 3.1), and a gene-replacement vector was constructed to replace 
the endogenous Mdm2 exon 12 sequences with a mutated exon 12  (Figure 3.2).  The 
introduced mutations also inserted a novel BcgI restriction digest site at codon 394, which 
allows direct detection of the mutated sequence by a PCR strategy.  Gene targeting 
experiments in PC3 (129SV) embryonic stem (ES) cells (O’Gorman et al., 1997) yielded 
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properly-targeted ES cell clones, as confirmed by Southern and PCR analyses (Figure 
3.3).  Blastocyst injection experiments produced several high-degree male chimeras that 
passed the A394 allele through their germ line while simultaneously deleting the floxed 
neomycin cassette due to expression of the protamine-Cre transgene (present in the PC3 
ES cells).  The resultant F1 and F2 generation mice were identified by Southern blot of 
genomic DNA and the presence of the A394 mutation in these mice was confirmed by 
utilizing the PCR-BcgI digest strategy (Figure 3.4).  This corroborated the Southern 
genotyping results and demonstrated retention of the mutation in both heterozygous 
(Mdm2A/+) and homozygous (Mdm2A/A) mice, but not in wild-type (Mdm2+/+) mice.  All 
genotyping techniques were reaffirmed by direct genomic sequencing of the exon 12 
region in F1 and F2 mouse genomic DNA (Figure 3.4). 
 
 
 
Figure 3.1: Sequence of the wild-type (S394) and mutant (A394) alleles at Mdm2 
codon 394.  The mutations in A394 also introduce a BcgI restriction digest site. 
 
 
 
Mdm2A/+ and Mdm2A/A mice are viable and were recovered from heterozygous 
intercrosses at Mendelian ratios (Table 3.1).  Because Mdm2-/- mice are embryonic lethal 
(Jones et al., 1995; Montes de Oca Luna et al., 1995), total ablation of Mdm2 function 
during development must not be occurring in Mdm2A/+ or Mdm2A/A mice.  We also did  
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Figure 3.2: Diagram of the targeting strategy used to generate the A394 allele.  The 
targeting vector contains a floxed neomycin cassette (neo) and a 3’ thymidylate kinase 
cassette (tk) for positive and negative drug selection, respectively.  The targeting vector 
was linearized and electroporated into PC3 ES cells, and proper homologous 
recombination was detected by Southern blot.  We took advantage of BamHI and SpeI 
sites found within the neo cassette to probe on both the 5’ (purple bar) and 3’ (yellow 
bar) ends, respectively.  PC3 cells have a protamine-cre recombinase transgene that 
excised the floxed neo cassette in chimeric male germ cells.  We utilized a final Southern 
blot with an EcoRI digest and 3’ probe (red bar). 
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not detect any differences between Mdm2+/+ and Mdm2A/A mice in body weights at 8 
weeks of age (Mdm2+/+ 25.67±2.9 grams and Mdm2A/A 24.3±4.2 grams), in male-to-
female sex distribution (Mdm2+/+ 1:0.82 and Mdm2A/A 1:0.90), or in overall litter size 
(Mdm2+/+ 8.5±1.8 and Mdm2A/A 8.7±1.9).  Since mice with decreased p53 function have 
decreased fecundity (Levine et al., 2011), our results suggest that basal p53 activity is not 
perturbed in Mdm2A/A mice. 
 
 
 
 
 
Figure 3.3: Southern blots and genomic PCR in A394 targeted ES cells.  Initial 
Southern blot of ES cells (left).  DNA samples were digested with BamHI and probed 
with a 3’ external probe (yellow bar from Figure 3.2).  The neo cassette within the A394 
gene replacement vector inserted an exogenous BamHI site, resulting in the shorter band 
(3.9 kb) seen in the targeted ES cell clone in lane 2.  Southern blot of ES cells (center).  
DNA samples were digested with SpeI and probed with a 5’ external probe (purple bar 
from Figure 3.2).  The neo cassette within the A394 gene replacement vector inserted an 
exogenous SpeI site, resulting in the shorter band (10.5 kb) seen in the targeted ES cell 
clone in lane 2.  PCR-BcgI analysis of targeted ES cells (right). Primers flanking Mdm2 
codon 394 were used to amplify DNA samples from WT PC3 cells (lane 1), the targeted 
ES cell clone (lane 2), and the A394 gene replacement vector (lane 3), followed by BcgI 
digestion. 
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Figure 3.4: Southern blot, genomic PCR, and genotyping in A394 mice. Southern blot 
of F2 generation mice (top left).  DNA samples were digested with EcoRI and probed 
with a 3’ internal probe (red bar from Figure 3.2).  The A394 allele inserted an exogenous 
EcoRI site resulting in the shorter band (3.8 kb).  PCR-BcgI analysis of F2 generation 
mice (bottom left).  Primers flanking Mdm2 codon 394 were used to amplify DNA 
samples from Mdm2+/+, Mdm2A/+, and Mdm2A/A F2 generation mice, followed by BcgI 
digestion.  Representative DNA sequencing chromatograms of the Mdm2 394 codon 
from Mdm2+/+, Mdm2A/+, and Mdm2A/A F2 generation mice (right). 
 
 
 
Table 3.1: Mdm2A/+ and Mdm2A/A viability.  Mdm2A/+ and Mdm2A/A mice are viable and 
were observed at Mendelian ratios after heterozygous intercrosses (p=0.322). 
 
 
Because ATM phosphorylation of MDM2 Ser395 was previously observed in cell 
lines following IR treatment (Maya et al., 2001), we assessed the sensitivity of Mdm2A/A 
mice to whole body γ-irradiation.  We irradiated cohorts of Mdm2+/+, Mdm2A/A, and p53-/- 
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mice with a threshold-lethal dose of IR (8Gy).  As expected, 86% of Mdm2+/+ mice died 
by 16 days post-IR (Figure 3.5).  However, like p53-/- mice, Mdm2A/A mice were 
completely radioresistant, indicating that Mdm2 Ser394 phosphorylation regulates p53 
activity in vivo following DNA damage.  Likewise, reduced red and white blood cell 
counts indicative of hematopoietic syndrome were seen in Mdm2+/+ mice at 7 days 
following 8Gy treatment, whereas the irradiated Mdm2A/A mice showed little change in 
these levels compared with untreated mice (Figure 3.6).  
 
 
Figure 3.5: Survival in whole-body irradiated mouse cohorts.  Cohorts of Mdm2+/+ 
(n=14), Mdm2A/A (n=14), and p53-/- (n=8) mice were irradiated with 8Gy and survival 
was observed over 26 days. 
 
 
 
Activation of p53 by IR damage in mice induces apoptosis in radiosensitive organs such 
as small intestine, spleen, and thymus (Gudkov and Komarova, 2003).  To evaluate p53 
apoptotic function in these tissues, we treated Mdm2+/+, Mdm2A/A, and p53-/- mice with 
2Gy IR and 6 hours later assayed apoptosis by terminal deoxynucleotidyl transferase 
dUTP nick end labeling (TUNEL) and cleaved caspase-3 immunohistochemistry (Figure 
3.7).  Very few apoptotic cells were detected in the small intestine, spleen, or the thymus 
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of Mdm2A/A mice following DNA damage, whereas apoptosis was readily apparent in all 
of these tissues in irradiated Mdm2+/+ mice.  These studies indicate markedly reduced 
p53-dependent apoptotic function in Mdm2A/A mice after IR treatment. 
  
 
 
Figure 3.6: Complete blood counts in irradiated Mdm2+/+ and Mdm2A/A mice.  
Complete blood cell counts were obtained 7 days following 8Gy treatment (n=3 per 
genotype).  Standard deviation indicated by error bars.  Asterisks indicate a significant 
difference (p=0.01). 
 
 
To more accurately quantitate this IR-dependent effect, we utilized Annexin V 
and propidium iodide (PI) staining to assay apoptosis in ex vivo thymocytes by flow 
cytometry.  Mdm2+/+ thymocytes are sensitive to apoptosis due to p53-induced activation 
of pro-apoptotic Puma expression (Jeffers et al., 2003).  In agreement with the whole-
body IR results, Mdm2+/+ thymocytes treated with 2Gy IR displayed 3.1-fold more early 
apoptotic (Annexin Vhigh PIlow) cells at 12 hours compared to untreated Mdm2+/+ cells, 
whereas Mdm2A/A thymocytes displayed only a modest 1.5-fold increase in apoptotic cells 
and Mdm2A/A thymocytes showed no induction of apoptosis after DNA damage (Figure 
3.8).  
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Figure 3.7: Apoptosis in radiosensitive tissues of IR-treated Mdm2+/+ and Mdm2A/A  
mice.  Mdm2+/+, Mdm2A/A, and p53-/- mice were irradiated with 2Gy and were sacrificed 
6 hours later.  Small intestine, spleen, and thymus were harvested and stained for TUNEL 
or anti-cleaved caspase-3 (Casp-3).  Scale bars represent 250 µm. 
 
 
To establish that the decreased apoptosis in DNA damaged Mdm2A/A thymocytes 
is due to altered p53 function, we treated Mdm2+/+, Mdm2A/A, and p53-/- thymocytes with 
Nutlin-3a, a small-molecule inhibitor of Mdm2-p53 binding (Vassilev et al., 2004).  
Mdm2+/+ and Mdm2A/A thymocytes co-treated with Nutlin-3a and IR each stabilized p53 
after IR damage, and blocking the interaction of p53 with Mdm2 completely rescued the 
ability of p53 to induce apoptosis in Mdm2A/A thymocytes following DNA damage  
(Figure 3.9).  To confirm that Nutlin-3a treatment restored IR-induced apoptosis in 
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Mdm2A/A cells by inhibiting Mdm2-p53 signaling, we performed FACS analysis on 
Mdm2A/A thymocytes that were genetically deleted for p53.  As expected, the addition of 
Nutlin-3a failed to restore IR-induced apoptosis in Mdm2A/A cells lacking p53 (Figure 
3.10).    
 
 
Figure 3.8: Quantification of apoptotic cells in primary Mdm2+/+ and Mdm2A/A 
thymocytes.  Ex vivo thymocytes were either left untreated or irradiated with 2Gy for 12 
hours (n=3 per genotype).  Standard deviation indicated by error bars.  Asterisk 
(p=0.0001) and double asterisk (p=0.0001) indicate significant differences. 
 
 
To verify that the effect of the Mdm2 A394 mutation on IR-apoptosis was truly 
ATM-dependent, we repeated the apoptosis assays using the ATM-specific inhibitor 
KU55933 (Hickson et al., 2004).  Inhibition of ATM reduced apoptosis in irradiated 
thymocytes to levels observed in untreated cells in all genotypes (Figure 3.11).  
Additionally, the ATM inhibitor blocked the robust ATM activation and p53 protein 
stabilization induced by IR damage (Figure 3.11). 
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Figure 3.9: Nutlin-3a treatment affects p53 protein levels and apoptosis in Mdm2+/+ 
and Mdm2A/A thymocytes.  Western blot of thymocyte extracts (left).  Ex vivo cells were 
either untreated or irradiated with 2Gy for 1 hour, and all cells were then incubated with 
12 µM Nutlin-3a for 1 hour.  Quantification of apoptotic cells by flow cytometry (right).  
Ex vivo thymocytes were either left completely untreated or irradiated with 2Gy for 12 
hours and incubated with 12 µM Nutlin-3a 3 hours after IR (9 hours total) (n=3 per 
genotype).  Standard deviation indicated by error bars. 
 
 
 
Figure 3.10: Nutlin-3a has no effect on irradiated Mdm2A/A, p53-/- thymocyte 
apoptosis.  Ex vivo thymocytes were either left completely untreated or irradiated with 
2Gy for 12 hours and incubated with 12 µM Nutlin-3a 3 hours after IR (9 hours total) 
(n=3 per genotype).  Standard deviation indicated by error bars. 
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Figure 3.11: ATM activity is necessary for IR-induced apoptosis and p53 
stabilization.  Quantification of apoptotic cells by flow cytometry (left).  Ex vivo 
thymocytes were preincubated with 10 µM KU55933 for 1 hour.  Cells were then either 
left untreated or irradiated with 2Gy for 12 hours (n=3 per genotype).  Standard deviation 
indicated by error bars.  Western blot of thymocyte extracts (right).  Ex vivo thymocytes 
were either left untreated or preincubated with 10 µM KU55933 for 1 hour.  Cells were 
then either untreated or irradiated with 2Gy for 2 hours. 
 
 
To further investigate the lack of IR-induced p53 function in Mdm2A/A mice, we 
compared the stabilization and activity of p53 in Mdm2+/+ and Mdm2A/A radiosensitive 
tissues after DNA damage.  We first harvested whole spleen protein extracts 4 hours after 
whole-body IR treatment.  As expected, activation of the ATM kinase in Mdm2+/+ mice 
by 4Gy IR was readily detected, as judged by the extent of auto-phosphorylated ATM 
Ser1987, the mouse orthologue of human ATM Ser1981 (Pellegrini et al., 2006), and this 
tissue displayed robust IR-stabilization of p53 (Figure 3.12).  However, Mdm2A/A mice 
lack any detectable stabilization of the p53 protein, despite comparable activation of 
ATM by IR.  This lack of p53 protein upregulation in IR-treated Mdm2A/A spleen extracts 
corresponded with greatly decreased induction of the p53-target genes Puma, p21, Bax, 
and Noxa, as measured by quantitative real time PCR (Figure 3.13).  However, IR-treated 
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Mdm2A/A spleens did show a low-level activation of p53, as expression of p53 target 
genes was slightly elevated relative to levels in IR-treated p53-/- spleens. 
 
 
Figure 3.12: Western blot of Mdm2+/+ and Mdm2A/A whole spleen extracts.  Mice 
were either untreated or irradiated with 4Gy and spleens were harvested 4 hours later. 
 
 
 
 
 
 
Figure 3.13: Relative expression of p53 target genes in Mdm2+/+ and Mdm2A/A 
spleens determined by qRT-PCR.  Mice were either untreated or irradiated with 4Gy 
and spleens were harvested 4 hours later (n=3 per genotype).  Levels were normalized to 
untreated wild-type and are presented as the ratio of mRNA to Gapdh mRNA.  Standard 
deviation indicated by error bars.  Asterisks indicate a significant difference: double 
asterisk Puma p=0.002, p21 p=0.01, Bax p=0.003, Noxa p=0.002; single asterisk Puma 
p=0.01, p21 p=0.001, Bax p=0.01, Noxa p=0.008. 
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Similar results were seen at multiple time points in thymus extracts following 
whole-body IR treatment of mice (Figure 3.14).  The level of p53 protein in Mdm2+/+ 
thymus was upregulated by 6.4-fold (1 hour), 4.8-fold (2 hour), and 1.8-fold (4 hours) 
following 4Gy IR, whereas p53 levels in IR-treated Mdm2A/A thymus were upregulated by 
only 2.1-fold, 1.3-fold, and 1.2-fold at these respective time points.  Again, these 
differences were seen despite similar activation of the ATM kinase (Figure 3.14).   
 
 
Figure 3.14: Western blot of Mdm2+/+ and Mdm2A/A whole thymus extracts.  Mice 
were either untreated or irradiated with 4Gy for the indicated times. 
 
 
As observed in spleen, expression of the p53-target genes Puma and p21 were 
significantly reduced in Mdm2A/A thymus at all time points after IR treatment (Figure 
3.15).  Since the p53 protein is phosphorylated by ATM on p53 Ser18 in the treated 
Mdm2A/A thymus (Figure 3.14), the reduced levels of p53 target gene expression in this 
tissue are likely due to decreased p53 protein stabilization in Mdm2A/A mice after IR, and 
not due to failure of ATM to induce proper post-translational modification of p53.  
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Analysis of multiple p53 target genes in irradiated Mdm2+/+ and Mdm2A/A thymocytes 
using p53 signaling pathway PCR arrays confirmed reduced activation of multiple p53 
target genes in treated Mdm2A/A cells (Table 3.2).  These results reveal that Mdm2 Ser394 
phosphorylation is required in vivo for p53 stabilization and robust p53 activation after 
DNA damage. 
 
 
Figure 3.15: Relative expression of p53 target genes in Mdm2+/+ and Mdm2A/A 
thymus.  Mice were either untreated or irradiated with 4Gy and thymii were harvested 2 
or 4 hours later (n=3 per genotype).  Data are presented as the ratio of mRNA to Gapdh 
mRNA.  Standard deviation indicated by error bars.  Significant differences were seen 
between Mdm2+/+ and Mdm2A/A Puma at 2 (p=0.035) and 4 (p=0.002) hours and between 
Mdm2+/+ and Mdm2A/A p21 at 2 (p=0.0001) and 4 (p=0.0001) hours. 
 
 
Mdm2 destabilization in response to DNA damage has been shown previously 
(Stommel and Wahl, 2004), and we observed an initial decrease in Mdm2 protein in both 
Mdm2+/+ and Mdm2A/A tissues.  Interestingly, these Mdm2 levels recovered at 2 and 4 
hours in both genotypes, with more Mdm2 protein being present in Mdm2+/+ at these 
times compared to Mdm2A/A (Figure 3.15).  Interestingly, the phosphorylation status of 
Mdm2 Ser394 had no effect on the levels of MdmX, an Mdm2-related p53 regulatory 
protein, in this tissue.   
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Table 3.2: Mdm2+/+ and Mdm2A/A thymocyte target gene expression by PCR Array.  
Relative expression levels of p53 target genes in irradiated thymocyte extracts 
determined by qRT-PCR using Qiagen p53 Signaling Pathway PCR Arrays.  Cells were 
either untreated or irradiated with 2Gy and were harvested 4 hours later.  Data are 
presented as the fold increase in individual treated Mdm2+/+ and Mdm2A/A animals 
normalized to untreated WT levels and as the ratio of mRNA to Gapdh mRNA.  
 
 
We next wanted to determine why differences in p53 and Mdm2 levels are 
observed in irradiated Mdm2+/+ versus Mdm2A/A cells.  One possibility is that p53 and 
Mdm2 protein levels are initially lower in Mdm2A/A cells than in Mdm2+/+ cells, leading 
to an overall reduced DNA damage response in Mdm2A/A mice.  To test this, we carefully 
quantitated p53 and Mdm2 protein levels in untreated Mdm2+/+ and Mdm2A/A whole 
thymus extracts and found no significant difference in the levels of either p53 or Mdm2 
proteins at baseline (Figure 3.16).  These data support the similar baseline levels of 
apoptosis and gene expression that we observed in Mdm2+/+ and Mdm2A/A tissues in the 
absence of DNA damage (Figures 3.8, 3.9, 3.11, 3.13, and 3.15).  Furthermore, careful 
quantitation confirmed that there is less p53 protein and Mdm2 protein in Mdm2A/A 
thymus than in Mdm2+/+ thymus after IR (Figure 3.17).  Since baseline Mdm2 levels 
were equivalent in Mdm2A/A and Mdm2+/+ tissue, the reduced amount of Mdm2 and p53 
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in Mdm2A/A versus Mdm2+/+ tissues reflects a specific difference in the response of 
Mdm2A/A cells to DNA damage. 
 
 
Figure 3.16: Basal levels of p53 and Mdm2 protein in Mdm2+/+ and Mdm2A/A thymus.   
All mice were untreated (n=3 per genotype).  Quantified levels of p53 and Mdm2 relative 
to PI3K were normalized to WT. 
 
 
 
Figure 3.17: Quantified p53 and Mdm2 protein levels in irradiated Mdm2+/+ and 
Mdm2A/A thymus.   Mice were either untreated or irradiated with 4Gy for the indicated 
times.  Quantified levels of p53 and Mdm2 relative to PI3K were normalized to untreated 
wild-type. 
 
 
To further examine the effects of Mdm2 Ser394 phosphorylation on p53 and 
Mdm2 stability, we performed western blots using irradiated Mdm2+/+ and Mdm2A/A ex 
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vivo thymocytes.  Stabilization of p53 was detected in primary Mdm2+/+ thymocytes at 1 
to 2 hours post-IR, and p53 levels remained elevated in these cells 6 hours after IR 
damage (Figure 3.18).  In contrast, p53 stabilization was not apparent in Mdm2A/A 
thymocytes at these early time points after DNA damage, even though ATM was clearly 
activated by IR treatment.  Similar to whole thymus extracts, Mdm2 levels also appear 
decreased in irradiated Mdm2A/A thymocytes compared to IR-treated Mdm2+/+ cells.   
 
 
 
Figure 3.18: Western blot of Mdm2+/+ and Mdm2A/A thymocyte extracts.  Ex vivo cells 
were either untreated or irradiated with 2Gy for the indicated times. 
 
 
The increased levels in wild-type Mdm2 protein may be due to increased p53-
induced Mdm2 transcription, and indeed, like other p53-dependent targets, Mdm2 
transcripts are lower in the irradiated Mdm2A/A thymocytes (Figure 3.19).  Alternatively, 
the difference in Mdm2 protein levels after DNA damage may be due to decreased Mdm2 
protein stability in Mdm2A/A thymocytes compared to Mdm2+/+ cells.  To examine the 
effects of Mdm2 Ser394 phosphorylation on Mdm2 stability in vivo, we incubated 
untreated and irradiated Mdm2+/+ and Mdm2A/A thymocytes with the protein synthesis 
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inhibitor cycloheximide (CHX).  Although Mdm2 protein is relatively unstable in 
thymocytes, we found that IR treatment lead to further decreases in Mdm2 stability in 
both genotypes (Figure 3.20).  However, the stability of Mdm2 proteins in untreated and 
IR-treated Mdm2+/+ and Mdm2A/A thymocytes was comparatively indistinguishable.  
Therefore, our results indicate that the lower Mdm2 protein levels in Mdm2A/A 
thymocytes after DNA damage reflects less p53 activation of Mdm2 transcription in these 
cells and not reduced Mdm2-S394A protein stability. 
 
 
 
Figure 3.19: Relative expression levels of Mdm2 in irradiated thymocytes.  Cells were 
either untreated or irradiated with 2Gy for the indicated time points (n=3 per genotype).  
Data are presented as the ratio of mRNA to Gapdh mRNA.  Standard deviation indicated 
by error bars. 
 
 
The reduced p53 transactivation of p21 observed in the spleen and thymus of IR-
treated Mdm2A/A mice (Figures 3.13 and 3.15) suggests that Mdm2 Ser394 
phosphorylation may also impact p53 regulation of cell proliferation.  To examine this  
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Figure 3.20: Mdm2 protein stability in thymocytes.  Western blot of irradiated 
thymocytes treated with cycloheximide.  Cells were incubated with 50 µg/ml of CHX and 
either left untreated or irradiated with 2Gy for the indicated times.  Quantified levels of 
Mdm2 relative to PI3K were normalized to untreated wild-type. 
 
 
further, we assayed p53 function in Mdm2+/+ and Mdm2A/A MEFs.  No difference in the 
growth rate of Mdm2+/+ and Mdm2A/A cells was observed using a standard proliferation 
assay (Figure 3.21).  This result is in keeping with the equivalent low levels of p53 
observed in non-damaged Mdm2+/+ and Mdm2A/A tissues.  However, greater p53 protein 
stabilization was observed in Mdm2+/+ MEFs than in Mdm2A/A MEFs at 6 and 12 hours 
post-IR (Figure 3.22).  Likewise, transactivation of p21 was greater in Mdm2+/+ MEFs 
than in Mdm2A/A cells, and induction of Mdm2 transcripts was delayed in Mdm2A/A MEFs 
(Figure 3.23).  FACS analysis of Mdm2+/+, Mdm2A/A, and p53-/- MEFs at 18 and 45 hours 
post-IR revealed that Mdm2A/A cells are compromised in their ability undergo growth 
arrest after DNA damage (Figure 3.24).  However, as compared to p53-/- cells, the 
Mdm2A/A MEFs do retain the ability to undergo a partial growth arrest after IR damage.  
These data reveal that phosphorylation of Mdm2 Ser394 also governs the ability of 
Mdm2 to regulate p53-mediated cell growth arrest after IR. 
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Figure 3.21: Untreated Mdm2+/+ and Mdm2A/A MEF proliferation.  Cell numbers were 
counted each day (n=3 per genotype).  Standard deviation indicated by error bars. 
 
 
 
 
 
Figure 3.22: Western blot of Mdm2+/+ and Mdm2A/A MEF extracts.  Cells were either 
untreated or irradiated with 4Gy for the indicated times. 
 
 
 
 
 
Figure 3.23: Relative expression levels of p53 target genes in irradiated Mdm2+/+ and 
Mdm2A/A MEFs determined by qRT-PCR.  Cells were either untreated or irradiated 
with 4Gy for the indicated times. (n=3 per genotype).  Data are presented as the ratio of 
mRNA to Gapdh mRNA. Standard deviation indicated by error bars 
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Figure 3.24: Cell cycle arrest in IR treated Mdm2+/+ and Mdm2A/A MEFs.  Cells were 
treated with 4Gy IR for the indicated time points and then incubated with 
bromodeoxyuridine (BrdU) for 3 hours (n=3 per genotype).  Standard deviation indicated 
by error bars.  Asterisks indicate a significant difference: double asterisk 18 hours 
p=0.0318, 45 hours p=0.0126; single asterisk 18 hours, p=0.0004, 45 hours p=0.0001. 
 
 
Because ATM phosphorylation of Mdm2 Ser394 is necessary for robust p53 
activation after DNA damage, we wanted to test whether this post-translational 
modification alone was sufficient to induce p53 activity in untreated tissues.  To this end, 
we generated a different mouse model in which Mdm2 Ser394 was mutated to aspartic 
acid (S394D), thus mimicking a constitutively phosphorylated serine residue (Figure 
3.25).  We followed the same gene replacement strategy used to generate the S394A 
model (3.26).  We confirmed properly targeted ES cells (Figure 3.27) and the presence of 
the D394 allele in F2 generation mice (Figure 3.28).  We hypothesized that if 
phosphorylation of Mdm2 Ser394 is sufficient by itself to disrupt Mdm2 regulation of 
p53, then substitution of aspartic acid at codon 394 might lead to embryonic lethality in 
mice bearing functional p53 alleles (as is seen in Mdm2-null mice).  However, both 
heterozygous (Mdm2D/+) and homozygous (Mdm2D/D) mice proved to be viable, and both 
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genotypes were recovered from heterozygous intercrosses at Mendelian ratios (Table 
3.3).  The viability of this knock-in mutant suggests that baseline levels of p53 protein 
would be unchanged in this model compared to controls, and subsequent quantitation of 
p53 and Mdm2 protein levels in untreated thymus protein extracts revealed no significant 
differences between Mdm2+/+ and Mdm2D/D (Figure 3.29). 
 
 
Figure 3.25: Sequence of the S394 and mutant D394 alleles.  The mutations in D394 
also introduce a BclI restriction digest site. 
 
The viability of Mdm2D/D mice also suggests that either multiple DNA damage signals 
are needed to attenuate Mdm2 regulation and activate p53, or that the Mdm2 S394D 
mutation poorly mimics a phosphoserine residue.  The latter possibility would result in 
Mdm2D/D mice presenting with phenotypes similar to our Mdm2A/A model, because 
aspartic acid (like alanine) cannot be phosphorylated.  To test this, we treated Mdm2+/+ 
and Mdm2D/D mice with 4Gy whole-body irradiation and examined p53 stabilization in 
thymus cells at various early time points after DNA damage.  In contrast to what we 
observed in Mdm2A/A cells, p53 protein stabilization by IR damage in Mdm2D/D thymus 
extracts was comparable to Mdm2+/+ (Figure 3.30).  This p53 stabilization was also 
observed in IR-treated ex vivo thymocytes (Figure 3.30). 
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Figure 3.26: Diagram of the targeting strategy used to generate the D394 allele.  The 
targeting vector was linearized and electroporated into PC3 ES cells, and proper 
homologous recombination was detected by Southern blot.  We took advantage of BamHI 
and SpeI sites found within the neo cassette to probe on both the 5’ (purple bar) and 3’ 
(yellow bar) ends, respectively.  PC3 cells have a protamine-cre recombinase transgene 
that excised the floxed neo cassette in chimeric male germ cells.  We utilized a final 
Southern blot with an EcoRI digest and 3’ probe (red bar). 
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Figure 3.27: Southern blots and genomic PCR in D394 targeted ES cells.  Initial 
Southern blot of ES cells (left).  DNA samples were digested with BamHI and probed 
with a 3’ external probe (yellow bar from Figure 3.26).  The neo cassette within the D394 
gene replacement vector inserted an exogenous BamHI site, resulting in the shorter band 
(3.9 kb) seen in the targeted ES cell clone in lane 2.  Southern blot of ES cells (center).  
DNA samples were digested with SpeI and probed with a 5’ external probe (purple bar 
from Figure 3.26).  The neo cassette within the D394 gene replacement vector inserted an 
exogenous SpeI site, resulting in the shorter band (10.5 kb) seen in the targeted ES cell 
clone in lane 2.  PCR-BclI analysis of targeted ES cells (right).  Primers flanking Mdm2 
codon 394 were used to amplify DNA samples from wild-type PC3 cells (lane 1), the 
targeted ES cell clone (lane 2), and the D394 gene replacement vector (lane 3), followed 
by BclI digestion. 
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Figure 3.28: Southern blot, genomic PCR, and genotyping in D394 mice.  Southern 
blot of F2 generation mice (top left).  DNA samples were digested with EcoRI and probed 
with a 3’ internal probe (red bar from Figure 3.2).  The D394 allele inserted an exogenous 
EcoRI site resulting in the shorter band (3.8 kb).  PCR-BclI analysis of F2 generation 
mice (bottom left).  Primers flanking Mdm2 codon 394 were used to amplify DNA 
samples from Mdm2+/+, Mdm2D/+, and Mdm2D/D F2 generation mice, followed by BclI 
digestion.  Representative DNA sequencing chromatograms of the Mdm2 394 codon 
from Mdm2+/+, Mdm2D/+, and Mdm2D/D F2 generation mice (right). 
 
 
 
Table 3.3: Mdm2D/+ and Mdm2D/D viability.  Mice either heterozygous or homozygous 
for the D394 allele are viable and were observed at Mendelian ratios after heterozygous 
intercrosses (p=0.76). 
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Figure 3.29: Basal levels of p53 and Mdm2 protein in Mdm2+/+ and Mdm2D/D 
thymus.    All mice were untreated (n=3 per genotype).  Quantified levels of p53 and 
Mdm2 relative to PI3K were normalized to wild-type. 
 
 
  Likewise, the pattern of Mdm2 protein destabilization followed by recovery was 
equivalent between the Mdm2+/+ and Mdm2D/D tissues (Figure 3.30), which reflects the 
equal induction of Mdm2 transcript levels seen in DNA damaged thymocytes (Figure 
3.31).  Puma transcript levels were also similarly increased in the IR-treated Mdm2+/+ 
and Mdm2D/D cell (Figure 3.31), and the levels of DNA damage-induced apoptosis were 
 
 
 
Figure 3.30: Western blots of Mdm2+/+ and Mdm2A/A whole thymus and thymocyte 
extracts.  Western blot of whole thymus extracts (left).  Mice were either untreated or 
irradiated with 4Gy for the indicated times.  Quantified levels of p53 and Mdm2 relative 
to PI3K were normalized to untreated wild-type.  Western blot of thymocyte extracts 
(right).  Ex vivo cells were either untreated or irradiated with 2Gy for the indicated times.  
PI3K was used as a loading control. 
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the same between Mdm2+/+ and Mdm2D/D thymocytes at 12 hours after IR treatment 
(Figure 3.32).  Similar results were obtained in thymocytes at 24 hours post-IR, as well as 
in thymocytes isolated 48 hours after whole-body IR in Mdm2+/+, Mdm2D/D, and p53-/- 
mice (Figure 3.33).  Collectively, these findings demonstrate that Mdm2 S394D mimics 
the effects of the phosphorylated Mdm2 Ser394 protein in Mdm2+/+ mice after DNA 
damage.  As baseline levels of p53 protein and apoptosis in non-damaged Mdm2+/+ and 
Mdm2D/D cells are the same in these assays, the mimicking of Mdm2 Ser394 
phosphorylation in Mdm2D/D thymocytes is not sufficient in the absence of other DNA 
damage-induced signals to induce p53 activation.  Alternatively, different 
phosphorylation sites on Mdm2 may be affected by either of the two knock-in mutants 
and could cause this difference in the DNA damage responses.  The effect of MDM2 
phosphorylation of Y394 modification has previously been tested, but the effect on other 
Mdm2 posttranslational modifications remain to be studied (Goldberg et al., 2002).    
 
To confirm the effects of this Mdm2 Ser394 phospho-mimic in cell growth, 
Mdm2+/+ and Mdm2D/D MEFs were analyzed for cell proliferation (Figure 3.34).  As with 
Mdm2A/A MEFs, the Mdm2D/D MEFs proliferated at the same rate as Mdm2+/+ MEFs in 
culture.  However, IR-treatment of Mdm2D/D MEFs induced p53 stabilization at levels 
similar to IR-treated Mdm2+/+ MEFs (Figure 3.35), and IR damage induced an equivalent 
p53-mediated reduction in S phase in both Mdm2+/+ and Mdm2D/D cells (Figure 3.36). 
 
Previous in vitro work has established that the Wip1 phosphatase can de-
phosphorylate multiple ATM targets, including human ATM Ser1981, p53 Ser15, and 
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MDM2 Ser395 (Shreeram et al., 2006a; Lu et al., 2005; Lu et al., 2007).  This de-
phosphorylation has been proposed to return DNA damage signaling to basal levels once 
the DNA damage has been resolved.  Since Wip1 cannot de-phosphorylate the Mdm2- 
S394D residue, we hypothesized that Mdm2D/D and Mdm2+/+ mice might have 
differences in the duration of Mdm2-p53 signaling after IR treatment.  Therefore, we 
analyzed p53 stabilization and activity at later time points in the DNA damage response.  
Like Mdm2D/D thymocytes (Figure 3.30), Mdm2+/+ and Mdm2D/D spleen samples had 
equal levels of ATM activity and p53 levels at 4 hours post-IR.  However, the level of 
p53 protein remained persistently elevated at 8 hours post-IR in Mdm2D/D extracts, 
despite the reduction in ATM activity and similar levels of Mdm2 by this later time point 
(Figure 3.37).   
 
 
 
Figure 3.31: Relative expression of p53 target genes in Mdm2+/+ and Mdm2D/D 
thymocytes determined by qRT-PCR.  Cells were either untreated or irradiated with 
2Gy for 2 or 4 hours (n=3 per genotype).  Data are presented as the ratio of mRNA to 
Gapdh mRNA.  Standard deviation indicated by error bars. 
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Figure 3.32: Quantification of apoptotic cells in primary Mdm2+/+ and Mdm2D/D 
thymocytes.  Ex vivo thymocytes were isolated and were either left untreated or 
irradiated with 2Gy for 12 hours (n=3 per genotype).  Standard deviation indicated by 
error bars. 
 
 
 
Figure 3.33: Quantification of apoptotic cells in ex vivo and whole-body             
irradiated Mdm2+/+ and Mdm2D/D thymocytes.  Ex vivo thymocytes were either left 
untreated, irradiated with 2Gy for 24 hours (left), or irradiated with 2Gy for 48 hours 
(n=3 per genotype).  Standard deviation indicated by error bars.  
 
 
 87 
 
A similar response pattern was seen in primary thymocytes.  Although p53 was 
stabilized to a similar extent in Mdm2+/+ and Mdm2D/D mice at early time points after IR 
damage (Figure 3.30), p53 levels remain elevated in Mdm2D/D thymocytes at 12 hours 
post-IR, whereas p53 stabilization is less obvious at this later time point in Mdm2+/+ cells 
(Figure 3.38).  As in spleen, the elongated duration of p53 stabilization in Mdm2D/D 
thymocytes was seen well after resolution of the DNA damage response, as indicated by 
the absence of phospho-ATM at 12 hours post-IR, and despite the presence of Mdm2.   
 
 
 
 
Figure 3.34: Untreated Mdm2+/+ and Mdm2D/D MEF proliferation.  Cell numbers 
were counted each day (n=3 per genotype).  Standard deviation indicated by error bars. 
 
 
 
 88 
 
Figure 3.35: Western blot of Mdm2+/+ and Mdm2D/D MEF extracts.  Cells were either 
untreated or irradiated with 4Gy for the indicated times. 
 
 
 
Figure 3.36: Cell cycle arrest in IR treated Mdm2+/+ and Mdm2D/D MEFs.  Cells were 
treated with 4Gy IR for 18 hours or 8Gy IR for 45 hours and incubated with BrdU for 3 
hours (n=3 per genotype).  Standard deviation indicated by error bars. 
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Figure 3.37: Western blot of Mdm2+/+ and Mdm2D/D whole spleen extracts.  Mice 
were either untreated or irradiated with 4Gy and spleens were harvested either 4 or 8 
hours later. 
 
 
 
 
Figure 3.38: Western blot of Mdm2+/+ and Mdm2D/D whole thymocyte extracts.  Ex 
vivo cells were either untreated or irradiated with 2Gy for either 12 or 18 hours. 
 
 
The elongated p53 response in Mdm2D/D thymocytes was reflected by increased 
levels of Puma, p21, Mdm2, and Wip1 expression found in these cells at 12 and 18 hours 
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post-IR (Figure 3.39), and p53 signaling pathway PCR array analysis of additional p53 
target genes confirmed that p53 activation remained elevated in Mdm2D/D thymocytes 
relative to Mdm2+/+ levels at 12 hours following IR (Table 3.4).  
 
 
Figure 3.39: Relative expression of p53 target genes in Mdm2+/+ and Mdm2D/D 
thymocytes determined by qRT-PCR.  Cells were either untreated or irradiated with 
2Gy for the indicated times (n=3 per genotype).  Data are presented as the ratio of mRNA 
to Gapdh mRNA. Standard deviation indicated by error bars. 
 
 
 
 
Table 3.4: Mdm2+/+ and Mdm2D/D thymocyte target gene expression by PCR Array.  
Relative expression levels of p53 target genes in irradiated thymocyte extracts 
determined by quantitative real time PCR using Qiagen p53 Signaling Pathway PCR 
Arrays.  Cells were either untreated or irradiated with 2Gy and were harvested 12 hours 
later.  Data are presented as the fold increase in individual treated Mdm2+/+ and Mdm2D/D 
animals normalized to untreated WT levels and as the ratio of mRNA to Gapdh mRNA. 
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Finally, to explore the importance of Mdm2 Ser394 phosphorylation in p53-
mediated tumor suppression, we established cohorts of Mdm2+/+, Mdm2A/A, and Mdm2D/D 
mice and performed a tumor assay.  In 24 months, 20 of 31 (65%) Mdm2A/A mice 
developed spontaneous tumors, whereas only 1 of 24 (4%) Mdm2D/D mice presented with 
a tumor of the salivary gland epithelium (Figure 3.40).  None of the Mdm2+/+ mice 
presented with a tumor during this interval.  Most of the Mdm2A/A tumors arose between 
18-24 months of age, which closely resembles previous p53+/- tumor curves (Harvey et 
al., 1993; Jacks et al., 1994).  Like other mouse models with diminished Atm activity, 
most of the tumors (13/20; 65%) were found to be T-cell derived lymphomas as staining 
for the T-cell marker CD3 (Figure 3.41).  The remaining Mdm2A/A tumors displayed 
severe splenomegaly and cellular infiltration in the liver and kidneys.  One of these 
 
 
Figure 3.40: Spontaneous tumor cohorts.  Spontaneous tumorigenesis in Mdm2+/+ 
(n=50), Mdm2A/A (n=31), and Mdm2D/D (n=24) mice.   
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Figure 3.41: Representative CD3 and B220 staining in Mdm2A/A lymphomas.  
Representative tumor sections from an Mdm2A/A T-cell lymphoma (mesenteric lymph 
node, left) and an Mdm2A/A B-cell lymphoma (spleen, right).  Tissue sections were stained 
with hematoxylin and eosin (H&E), anti-CD3, or anti-B220.  Scale bars are 100 µm. 
 
tumors stained positive for B220 and displayed expansion of the white pulp in the spleen, 
indicative of B cell lymphoma (Figure 3.41).  Sequencing of p53 transcripts isolated from 
four randomly selected tumors indicated Mdm2+/+ p53 expression levels and no p53 
mutations in these Mdm2A/A samples.  These results reveal that post-translational 
modification of Mdm2 Ser394 impacts p53-mediated tumor suppression as well as the 
p53 DNA damage response in vivo.   
 
Discussion 
Activation of the p53 tumor suppressor by DNA damage and a role for DNA 
damage-induced kinases in p53 activation has been well established.  However, in vivo 
analyses have revealed that phosphorylation of p53 by these kinases serves only to fine-
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tune the p53 response without having a large effect on p53 stability (Toledo and Wahl, 
2006).  Mdm2 is also a potential target for post-translational modification by DNA 
damage- induced kinases such as ATM (Maya et al., 2001), but there has been no direct 
in vivo analysis of the effects of Mdm2 phosphorylation on p53 stability and functions.  
 
In our present study utilizing mouse models of Mdm2 Ser394 phosphorylation, 
we provide direct evidence that ATM phosphorylation of Mdm2 Ser394 regulates the 
ability of Mdm2 to destabilize p53 in vivo, and that this signaling impacts p53-mediated 
apoptosis and tumor suppression.  Mdm2A/A mice lack p53-dependent physiological 
responses in radiosensitive organs after IR treatment resulting in phenotypes that nearly 
match those seen in IR treated p53-/- mice: radioresistance, greatly reduced p53 target 
gene induction, and greatly reduced apoptosis.  Importantly, the differences between 
Mdm2A/A and Mdm2+/+ mice were seen only in irradiated mice and tissues, as baseline 
levels were similar in all assays.  This owes to the conservation of Mdm2 structure and 
function in the S394A protein, and indicates that the only difference between the wild-
type and mutant Mdm2 protein is the phosphorylation status of Ser394 after cellular 
stress.  It is likely that the compromised p53 transactivation and the reduced number of 
cells undergoing apoptosis and cell cycle arrest are due to the lack of p53 protein 
accumulation in DNA damaged Mdm2A/A cells.  Thus, phosphorylation of Mdm2 Ser394 
by the ATM kinase is a major regulator of p53 stability and the subsequent p53-mediated 
DNA damage response in multiple tissue types.  
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Although the levels of p53 induction and activation are equivalent at early time 
points after IR in Mdm2+/+ and Mdm2D/D cells, p53 protein levels and activities remain 
elevated in Mdm2D/D cells at later time points after IR treatment (Figures 3.37-3.40).  In 
contrast, the DNA damage response in Mdm2+/+ cells begins to wane after 6 hours post-
IR, coincident with the induction of Wip1 expression (Figures 3.38 and 3.39).  Since 
Wip1 is unable to dephosphorylate the Mdm2 S394D residue, elevation of p53 functions 
in Mdm2D/D cells at later time points after IR indicates that Mdm2-S394 phosphorylation 
also regulates the duration of the p53 response.  However, p53 levels and activities 
eventually return to baseline in the Mdm2D/D cells, possibly due to the eventual loss of 
other secondary modifications to Mdm2 or p53 (which remain to be reliably detected and 
tested).  These findings are in keeping with a proposed role for Wip1 as gatekeeper of the 
Mdm2-p53 autoregulatory loop (Lu et al., 2007).  Collectively, our results indicate that 
ATM phosphorylation of Mdm2 Ser394 is necessary but not sufficient to induce a robust 
p53 response to IR. 
 
Interestingly, p53 tumor suppressor function is deficient in untreated S394A mice, 
as 65% of these mice developed spontaneous lymphomagenesis in the absence of 
exogenous IR treatment.  Since our data indicate that p53 levels and activities are 
identical between Mdm2+/+ and Mdm2A/A cells in the absence of DNA damage, the 
stochastic nature of endogenous DNA damage signaling arising from inappropriate 
oncogene activation or DNA replication errors may account for this rather long latency 
period.  Tumor formation in our Mdm2A/A model is in keeping with previous reports of a 
role for ATM–p53 signaling and p53 activation of the pro-apoptotic gene Puma in p53-
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mediated suppression of lymphoma formation (Jeffers et al., 2003; Sluss et al., 2010).  
Likewise, the reduced capacity of p53 to suppress growth after DNA damage in Mdm2A/A 
cells may also contribute to the spontaneous tumorigenic phenotype of Mdm2A/A mice.  It 
remains to be seen if phosphorylation of Mdm2 Ser394 by ATM also regulates p53-
mediated suppression of tumors induced by sub-lethal doses of radiation or the forced 
expression of activated oncogenes.   
 
Transfection-based experiments have determined that mutation of six separate 
ATM phosphorylation sites in the carboxy-terminus of MDM2, including Ser395, alters 
MDM2 protein oligomerization, E3-ligase activity, and the interaction of MDM2 with 
p53 (Cheng et al., 2009; Cheng et al., 2011).  Because p53 activity is not totally ablated 
in the Mdm2A/A model, these additional ATM targets on Mdm2 may contribute to full p53 
activation after DNA damage.  Furthermore, a recent study found that ATM 
phosphorylation of MDM2 Ser395 led to increased p53 mRNA translation, which 
suggests that MDM2 may be necessary for p53 protein upregulation after DNA damage 
(Gajjar et al., 2012).  Diminished Mdm2 E3 ligase activity and phospho-Mdm2-
dependent upregulation of p53 would each explain the seemingly paradoxical results of 
having decreased p53 levels and activities in the absence of Mdm2 protein in IR-treated 
Mdm2A/A thymus extracts.  These mechanisms would also explain the increased p53 
activation at later times of the DNA damage response in Mdm2D/D cells despite nearly 
equivalent levels of Mdm2 compared to Mdm2+/+.  Our in vivo data are in keeping with 
both of these proposed models and confirm a significant role for Mdm2 S394 
phosphorylation in the p53 DNA damage response. 
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In conclusion, our study reveals that ATM phosphorylation of Mdm2 at serine 
residue 394 is a critical regulator of Mdm2-p53 signaling.  Phosphorylation of this Mdm2 
residue by ATM following DNA damage is necessary for p53 stabilization, thereby 
upregulating p53 activity and activating p53 downstream functions in primary cells and 
tissues.  Furthermore, the phosphorylation status of Mdm2 Ser394 governs the duration 
of the p53 response, underscoring the importance of this single phosphorylation target in 
regulating Mdm2-p53 signaling and p53-mediated tumor suppression.  Full 
understanding of the multiple post-translational modifications that influence p53 
signaling will likely assist in developing better molecular diagnostics and therapeutics for 
human cancer patients. 
 
Materials and Methods 
Generation of S394A and S394D mice 
The targeting constructs contain a subcloned fragment of the Mdm2 genomic sequence 
(129Sv strain).  Site-directed mutagenesis was performed (Stratagene #200523).  The 
targeting vectors were sequenced to ensure that no unwanted mutations were introduced.  
PC3 ES cells were electroporated with each targeting vector.  Homologous recombination 
was detected by Southern blot using 5’ and 3’ external probes after SpeI and BamHI 
restriction digests, respectively.  Targeted cells were microinjected into E3.5 blastocysts 
(C57BL/6 strain), and the embryos were surgically implanted into pseudopregnant foster 
mice by standard procedures.  Transmission of the knock-in allele and excision of the neo 
cassette in F1 offspring of male chimeric mice was confirmed by digestion with EcoRI 
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followed by Southern analysis using a 3’ internal probe described previously (Steinman 
and Jones, 2002). 
 
Mice 
All mice used in this study were on a mixed 129Sv×C57Bl/6 background.  Sequencing of 
DNA samples was performed by Sequegen.  All mice and cells were irradiated with a 
cesium-137 source (Gammacell 40).  Animals in the spontaneous tumor cohorts or IR-
treated cohorts were killed if tumor burden was apparent or when moribund.  Animals 
were maintained and used in accordance with federal guidelines and those established by 
the Institutional Animal Care and Use Committee at the University of Massachusetts 
Medical School. 
 
Mdm2 S394A and Mdm2 S394D Genotyping 
Mouse tail DNA was amplified by PCR using the following primers: Forward 5’- 
AAAGATGCTGGACCCTTCGTGAGA-3’ and Reverse 5’- 
GCACACGTGAAACATGACATGAGG-3’.  This produces a 430 base pair (bp) PCR 
fragment that must then be digested by specific restriction enzymes.  For Mdm2 S394A, 
1 µl NEB Buffer 3 supplemented with S-adenosylmethionine (SAM) and 1 µl BcgI was 
added directly to the PCR reaction tube and incubated at 37 °C for 1 hour.  For Mdm2 
S394D, 1 µl BclI was added directly to the PCR reaction tube and incubated at 50 °C for 
1 hour.  These digestions each approximately bisect the DNA fragment so that the WT 
and mutant alleles can be distinguished by running on a 1% agarose gel.   
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Histology 
Tissues were fixed in 10% formalin.  Irradiated tissue sections (5µm) were stained with 
anti-cleaved caspase-3 antibody (Cell Signaling #9661) or stained for TUNEL using the 
In Situ Cell Death Detection Kit, POD (Roche 11684817910).  Tumor samples were 
stained with anti-CD3 (Abcam ab16044) or anti-CD45R/B220 (BD Pharmingen).  All 
staining was performed by the UMMS Diabetes and Endocrinology Research Center 
Morphology Core. 
 
Western Blotting and Reagents 
Tissues and cells were lysed in NP-40 lysis buffer (50 mM Tris–HCl, pH 7.5; 150 mM 
NaCl; 0.5% NP-40; 20% Glycerol) supplemented with 1×protease inhibitor cocktail 
(Roche).  Protein extracts were analyzed by standard western blotting with the following 
antibodies: p53 (1C12), phospho-Atm Ser1987 (10H11.E12), and phospho-p53 Ser18 
(#9284) from Cell Signaling; Mdm2 (mix of sc-812 and sc-1022) and lamin A/C (sc-
6215) from Santa Cruz; MdmX (MDMX-82) and tubulin (T5168) from Sigma; PI3K 
(#06-496) from Upstate; actin (ab8229) from Abcam.  Nutlin-3a (N6287) and 
cycloheximide (C4859) were from Sigma.  PI3K and tubulin were used as loading 
controls.  KU55933 (118502) was from Calbiochem.  The CIP (M0290) and phosphatase 
treatment protocol were from NEB.  Protein levels in Figure 3C were quantified by 
densitometry using the ImageJ software.  All other protein quantification was performed 
using the Chemidoc XRS+ Molecular Imaging System from BioRad. 
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Gene Expression Analysis 
Total mRNA was isolated according to the Trizol Reagent protocol (Invitrogen) and 
cDNA was generated using the SuperScript II First Strand Synthesis Kit (Invitrogen).  
The following primers were used in qRT-PCR: 
p21: 5’-TGAGGAGGAGCATGAATGGAGACA-3’ 
5’-AACAGGTCGGACATCACCAGGATT-3’, 
Puma: 5’-CCTGGAGGGTCATGTACAATCT-3’ 
5’-TGCTACATGGTGCAGAAAAAGT-3’, 
Bax: 5’-CTGAGCTGACCTTGGAGC-3’ 
5’-GACTCCAGCCACAAAGATG-3’, 
Noxa: 5’-CCACCTGAGTTCGCAGCTCAA-3’ 
5’-GTTGAGCACACTCGTCCTTCA-3’, 
Mdm2: 5’-GCATTCTGGTGATTGCCTGGATCA-3’ 
5’-AGACTGTGACCCGATAGACCTCAT-3’ 
Gapdh: 5’-TGGCAAAGTGGAGATTGTTGCC-3’ 
5’-AAGATGGTGATGGGCTTCCCG-3’. 
All data are presented as the ratio of mRNA to Gapdh mRNA. 
For the Qiagen p53 PCR Array experiments, mRNA was isolated using the RNeasy kit 
(74104) with DNase (79254) from Qiagen.  cDNA was synthesized using the RT2 First 
Strand Kit (330401) from Qiagen.  p53 PCR Arrays (PAMM-027C) were run according 
to manufacturer’s protocol using the RT2 SYBR Green ROX qPCR Mastermix (330520) 
from Qiagen.   
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Flow Cytometry 
For apoptosis, samples were treated according to the Annexin V-FITC Apoptosis 
Detection Kit I protocol (BD Pharmingen #556547).  Early apoptotic cells (Annexin Vhigh 
PIlow) were quantitated and presented.  For cell cycle arrest, treated MEFs were pulse 
labeled with 60µM bromodeoxyuridine (BrdU) for 3 hours.  Cells were then trypsinized, 
fixed in 70% ethanol overnight, incubated with anti-BrdU antibody (Becton Dickinson 
#347583) and PI, and analyzed by flow cytometry.  Data are presented as the percentage 
of cells in S phase in the treated samples compared to the untreated samples.  Flow 
cytometry was performed by the UMASS Medical School Flow Cytometry Core Lab.   
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UNPUBLISHED AND ONGOING WORK 
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Foreword 
The results presented in Chapter 3 of this dissertation revealed the necessity of 
Mdm2 Ser394 in the p53-dependent response to IR.  However, p53-Mdm2 signaling has 
a role in many cellular processes, and the role of Mdm2 Ser394 phosphorylation in 
response to these alternate stressors remains to be tested.  Additionally, older Mdm2A/A 
mice displayed greatly increased spontaneous tumorigenesis, revealing a role for this 
residue in tumor suppression even in the absence of exogenous IR treatment.  We have 
conducted preliminary experiments to further characterize the role of Mdm2 Ser394 in 
these p53-dependent effects.       
 
Introduction 
The positive correlation between the tumorigenic potential of primary cells and 
the incidence of tumorigenesis in the corresponding animal model is substantiated in  
p53-/- mice and cells.  MEFs derived from p53-/- embryos have been used to determine the 
role of p53 in various cell culture assays such as low-density plating stress experiments 
and immortalization assays.  Previous studies have shown that p53 restricts the survival 
and growth of cells at very low densities, as p53-/- MEFs readily grow robust colonies 
under these conditions (Harvey et al., 1993; Jones et al., 1996).  Likewise, p53 limits the 
immortalization of MEFs that undergo stress and increased mutations caused by serial 
plating.  In these experiments, wild-type MEFs fail to immortalize in culture due to 
decreased viability and increased senescence, while p53-/- MEFs immortalize after only a 
few passages in culture (Harvey et al., 1993; Jones et al., 1996).  These results mirror the 
increased tumorigenesis seen in p53-/- mice, and established the potential link between 
 103 
p53 responses under cell culture conditions and the ability to inhibit tumor initiation and 
development at the organismal level (Donehower et al., 1992).     
 
As p53 activity is critical in limiting spontaneous tumorigenesis, it is not 
surprising that p53 also suppresses tumors that are initiated by cellular stressors such as 
ionizing radiation and activated oncogene expression.  We have previously shown that 
wild-type mice that are irradiated with 8Gy die in a p53-dependent manner at 2-3 weeks 
post-IR (see Figure 3.5).  However, previous reports have shown that p53 protects against 
DNA damage-induced tumorigenesis in mice treated with sub-lethal doses of IR (Kemp 
et al., 1994).  In this study, wild-type mice treated with 4Gy survived up to 80 weeks 
with 100% of the mice being tumor free.  Conversely, IR-treated p53+/- mice died by 55 
weeks of age and p53-/- mice died by 17 weeks of age due to increased incidences of 
lymphomas and sarcomas.  These tumors arose significantly faster than untreated p53+/- 
and p53-/- control cohorts, revealing the importance of p53 signaling in protecting against 
total body IR-induced tumorigenesis in mice (Kemp et al., 1994; Harvey et al., 1993).  
 
A common mouse model that has been used to examine the cellular response to 
activated oncogenes is the Eµ-Myc transgenic model (Adams et al., 1985).  These mice 
bear the c-myc oncogene under the control of the immunoglobulin heavy chain enhancer 
so that c-myc is overexpressed in progenitor B cells and, therefore, these mice develop 
rapid B-cell lymphomagenesis.  Multiple members of the p53 regulatory pathway, 
including ATM and Wip1, have been shown to be important in determining tumor free 
survival in these mice, as the genetic disruption of p53 function and regulation results in 
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increased lymphomagenesis rates (Eischen et al., 1999; Schmitt et al., 1999; Maclean et 
al., 2007; Garrison et al., 2008; Sluss et al., 2010).  As Mdm2 Ser394 has been shown to 
be an important regulatory site for ATM-dependent p53 activation, we expect this site to 
be crucial for p53 tumor suppression in Eµ-Myc mice.  Preliminary experiments 
describing the effects of Mdm2 Ser394 status on the function of p53 in cell culture stress, 
IR-induced tumorigenesis and survival, and oncogene-induced lymphomagenesis will be 
presented in this Chapter. 
 
Results 
It is clear from our previous results that Mdm2 Ser394 phosphorylation is 
necessary for p53-dependent cell-cycle arrest in MEFs treated with γ-irradiation.  To 
further characterize the necessity of this Mdm2 residue in response to other DNA 
damaging agents, we repeated the BrdU incorporation assays using the topoisomerase II 
inhibitors etoposide and doxorubicin and the topoisomerase I inhibitor camptothecin 
(Figure 4.1).  As expected, Mdm2+/+ cells treated with these reagents displayed a large 
decrease in cells in S phase.  Interestingly, p53-/- cell cycle profiles were unaffected by 
doxorubicin and camptothecin, but did undergo a partial cell cycle arrest in response to 
etoposide, albeit not to the same extent as Mdm2+/+ cells.  This likely owes to some p53-
independent effects in the cellular response to etoposide.  Importantly, the decline in S 
phase in treated Mdm2A/A cells showed no significant difference compared to Mdm2+/+ 
cells in all three genotoxic treatments.  These results suggest that, while Mdm2 Ser394 
phosphorylation is important in the response to IR in MEFs, alternate mechanisms must 
exist to activate p53 in response to these topoisomerase inhibitors.   
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Figure 4.1: Cell cycle arrest in Mdm2+/+ and Mdm2A/A MEFs treated with genotoxic 
drugs.  Cells were treated with 25 µM etoposide, 172 nM doxorubicin, or 300 nM 
camptothecin for 15 hours and were pulse-labeled with bromodeoxyuridine (BrdU) for 3 
hours (n=3 per genotype).  Standard deviation indicated by error bars. 
 
 
Because the Mdm2A/A mice exhibited enhanced tumorigenesis in the absence of 
exogenous stress, we determined that Mdm2 Ser394 phosphorylation may have roles in 
cellular stressors independent of DNA damage.  One known p53-dependent cellular stress 
that limits proliferation and growth in MEFs is low plating density.  We plated Mdm2+/+, 
p53-/-, and Mdm2A/A MEFs at 104 cells/10cm plate and cell colony formation was 
observed after 2 weeks in culture (Figure 4.2).  We observed significantly more Mdm2A/A 
colonies that were greater than 2mm in diameter compared with Mdm2+/+.  However, the 
number of Mdm2A/A colonies was greatly reduced compared to p53-/-, suggesting only a 
modest effect of Mdm2 Ser394 phosphorylation on low plating stress responses.    
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Figure 4.2: Low plating density assay.  Representative MEF lines from low plating 
density assays.  Mdm2+/+, p53-/- and Mdm2A/A MEFs were plated at 104 cells/10 cm plate 
and grew for 14 days.  Cells were then stained with crystal violet and colonies larger than 
2 mm in diameter were counted.  Average number of colonies and standard deviations are 
presented (n=3 per genotype).      
 
 
 
Another well-studied assay that is dependent on functional p53 activity is the 3T3 
immortalization assay.  Serial passaging in culture leads to the accumulation of genetic 
mutations, which triggers p53-dependent cell growth suppression and eventual 
senescence to prevent immortalization and the potential for transformation in cells 
(Harvey et al., 1993; Jones et al., 1996).  Therefore, disrupted p53 function results in 
increased immortalization rates following serial passaging.  As p53-/- cells have no 
checkpoint, they readily immortalized (Figure 4.3).  Expectedly, Mdm2+/+ and Mdm2D/D 
cells failed to immortalize.  Surprisingly, Mdm2A/A cells were indistinguishable from the 
Mdm2+/+ and Mdm2D/D cells, which indicates that Mdm2 Ser394 is dispensable for p53-
dependent suppression of immortalization in this assay.  The 3T3 experiment was 
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subsequently repeated and the results in each of the curves were qualitatively 
comparable, as only the p53-/- cell lines spontaneously immortalized. 
 
 
 
Figure 4.3: 3T3 immortalization assay (n=3 per genotype).  Standard deviation 
indicated by error bars. 
 
 
 
Because Mdm2A/A mice have increased spontaneous tumorigenesis and a greatly 
diminished p53 response to IR, we wanted to determine if there is a role for Mdm2 
Ser394 phosphorylation in IR-induced tumorigenesis.  To test this we treated cohorts of 
Mdm2+/+, Mdm2A/A, and Mdm2D/D mice with a low dose of IR (6Gy) and observed their 
survival (Figure 4.4).  All treated mice showed characteristic hair greying, confirming 
that they had been irradiated.  However, none of the irradiated mice died before 200 days 
post-IR, which differs from the rapid lethality seen in mice treated with 8Gy (Figure 3.5).  
The survival of the irradiated mice was negatively affected in each genotype when 
compared to the respective spontaneous survival curves (see Figure 3.40); however, no 
obvious tumors developed in any of the irradiated mice regardless of genotype.  
Interestingly, while the Mdm2+/+ and Mdm2A/A survival rates nearly overlap, the Mdm2D/D 
mice were more protected from the low dose IR-induced death.   
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Figure 4.4: Survival in mouse cohorts irradiated with 6Gy.  Cohorts of Mdm2+/+ 
(n=11), Mdm2A/A (n=11), and Mdm2D/D (n=9) mice were irradiated with 6Gy and survival 
was observed over 450 days. 
 
 
The DNA damage-p53 signaling axis has been shown to be an important 
suppressor of oncogene-induced B-cell lymphomagenesis that develops in the Eµ-Myc 
transgenic mouse model (Eischen et al., 1999; Schmitt et al., 1999; Shreeram et al., 
2006b; Maclean et al., 2007; Garrison et al., 2008; Sluss et al., 2010).  Since we have 
shown that Mdm2 S394 phosphorylation is critical for the p53 response to DNA damage, 
we expect this posttranslational modification to be a critical signaling event in activating 
p53 in the Eµ-Myc mouse model.  To test this we crossed inbred C57Bl/6 (generation N8) 
Mdm2A/A mice to mice expressing the Eµ-Myc transgene and have generated 5 Mdm2A/+, 
Eµ-Myc mice and 1 Mdm2A/A, Eµ-Myc mouse to date.  All of these mice developed 
enlarged spleens and thymii and did not survive past 115 days.  While these cohorts are 
small, the survival rates are similar to other published Eµ-Myc tumor-free curves in mice 
with diminished ATM-p53 signaling, and further confirm the necessity for the ATM-
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Mdm2-p53 signaling axis in tumor suppression in response to the activated c-myc 
oncogene (Eischen et al., 1999; Schmitt et al., 1999; Shreeram et al., 2006b; Maclean et 
al., 2007; Garrison et al., 2008; Sluss et al., 2010).   
 
Discussion 
Our previous work demonstrated a critical role for Mdm2 Ser394 in the activation 
of the DNA damage response to IR and in suppressing spontaneous tumorigenesis.  The 
studies presented in this chapter were performed to explore the role of this residue in the 
p53 response to alternate cellular stressors, including different DNA damaging agents.   
Unexpectedly, Mdm2 S394 phosphorylation was dispensable for the cell cycle arrest after 
treatment with the cytotoxic drugs etoposide, doxorubicin, and camptothecin.  This may 
be due to additional, ATM-independent mechanisms that are activated by these drugs to 
inhibit Mdm2 function and allow p53 stability and activity.  One variable that could 
account for these differences is the time of exposure to these DNA damaging agents.  The 
IR doses used in our previous studies require minutes in the irradiator, where the ATM 
pathway may be the sole or predominant signaling mechanism.  The cytotoxic agents are 
present in the cell culture media for the total length of the assay, which could potentially 
activate auxiliary pathways that do not rely on the posttranslational status of Mdm2 
Ser394. 
 
We also sought to characterize the immortalization potential of Mdm2A/A MEFs 
via the 3T3 assay.  We have shown that most Mdm2A/A mice develop lymphomas 
relatively late in life (Figure 3.40).  Because these tumors arose even in the absence of 
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exogenous IR, we hypothesized that the differences may be due to a failure in p53 
signaling in response to accumulated mutations.  The serial passaging of MEFs in the 
3T3 assay could be argued to parallel the accumulated stress that occurs with age at the 
organismal level.  However, none of the Mdm2A/A MEF lines showed any spontaneous 
immortalization, suggesting that the response to accumulated mutations in the mice is 
similarly unaltered.  The tumors that develop in the Mdm2A/A model most likely arise 
from a variety of complicated processes that still need to be elucidated, such as the 
sensitivity to DNA double strand breaks.  This could be further tested using known, 
infrequent DNA restriction digest enzymes such as SecI or SalI to induced double strand 
breaks in the DNA.  This would isolate the response to the DNA damage rather than any 
other independent effects exhibited by ionizing radiation or genotoxic drugs. 
 
The results of the IR-induced tumorigenesis experiments were surprising.  Since 
the Mdm2A/A mice have severely impaired IR responses and develop lymphomas even in 
the absence of exogenous stress, we anticipated a greatly increased tumorigenesis rate in 
the Mdm2A/A mice compared to wild-type.  However, no tumors arose in the irradiated 
Mdm2A/A mice and the survival rates between Mdm2+/+ and Mdm2A/A mice were 
indistinguishable.  Conversely, we expected the Mdm2D/D mice to be protected from IR-
induced tumorigenesis since this model displayed slightly overactive p53 activity 
following irradiation.  This potential tumor protection in the Mdm2D/D model was unable 
to be tested, as no tumors were seen in any genotype; however, the Mdm2D/D mice did 
show an overall increase in survival.  While no obvious explanation of the deaths of the 
treated mice arose, bone marrow failure and an overall decrease in hematopoiesis are 
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likely candidates.  A possible explanation of the tumorigenesis results might be that the 
phenotypic effects of Mdm2 Ser394 in the response to IR are separate from its effects on 
p53 tumor suppression.  Very recent work utilizing p53 mutant mouse models has 
revealed that the tumor suppressive function of p53 may rely on the ability of p53 to 
regulate glucose metabolism rather than cell cycle arrest and apoptosis (Li et al., 2012).  
As altered metabolism plays an important role in facilitating tumor growth (Cairns et al., 
2011), the capability of Mdm2 Ser394 phosphorylation to regulate spontaneous 
tumorigenesis may be distinct from its role in regulating the DNA damage response.  
Further work on the ability of Mdm2 Ser394 to regulate p53-dependent expression of 
glycolytic genes such as TP53-induced glycolysis and apoptosis regulator (TIGAR) may 
unveil the Mdm2 Ser394-dependent mechanism(s) that regulate tumor suppression 
(Bensaad et al., 2006). 
 
Materials and Methods 
Mice 
Mice used in the IR-treated cohorts were on a mixed 129Sv×C57Bl/6 background, and 
mice used in the Eµ-Myc cohorts were on an inbred C57Bl/6 (generation N8) 
background.  All mice and cells were irradiated with a cesium-137 source (Gammacell 
40).  Animals in the spontaneous tumor cohorts or IR-treated cohorts were killed if tumor 
burden was apparent or when moribund.  Animals were maintained and used in 
accordance with federal guidelines and those established by the Institutional Animal Care 
and Use Committee at the University of Massachusetts Medical School. 
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Cell Cycle Arrest 
MEFs were either untreated or treated with 25 µM etoposide (Sigma E1385), 172 nM 
doxorubicin (Sigma D1515), or 300 nM camptothecin (Sigma C9911) and then pulsed 
labeled with 60 µM bromodeoxyuridine (BrdU) for 3 hours.  Cells were then trypsinized, 
fixed in 70% ethanol overnight, incubated with anti-BrdU antibody (Becton Dickinson 
#347583) and PI, and analyzed by flow cytometry.  Data are presented as the percentage 
of cells in S phase in the treated samples compared to the untreated samples.  Flow 
cytometry was performed by the UMASS Medical School Flow Cytometry Core Lab.   
 
Low Plating Assay 
MEFs were plated at 104 cells/10cm plate and allowed to grow in culture for 14 days.  
Cells were then briefly fixed in methanol and stained with 0.1% crystal violet for 30 
minutes.  The plates were then washed in PBS and colonies larger than 2mm in diameter 
were counted for each genotype. 
 
3T3 Immortalization Assay 
Triplicate cultures of three independent cell lines of each genotype were plated at a 
density of 5.5 X 104 MEFs/cm2 on 10cm plates.  These independent cell lines were 
harvested every third day, pooled, counted, and replated under the same conditions.  As 
cell numbers decreased, the plates used were adjusted to maintain the original cell 
density.   
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Foreword 
The p53-Mdm2 signaling pathway has been extensively studied over the years, 
and genetically engineered mouse models have played important roles in determining the 
validity and significance of results produced in vitro.  The novel work presented 
throughout this dissertation has revealed new roles for Mdm2-p53 signaling in 
maintaining tissue homeostasis and stem cell function, and has demonstrated the 
importance of a single Mdm2 amino acid residue in controlling the cellular response to 
DNA damage and limiting IR-induced survival and spontaneous tumorigenesis.  While 
the studies presented in the preceding Chapters have contributed to the Mdm2-p53 field, 
additional experiments are still needed in order to fully uncover the physiological roles of 
the Mdm2-p53 signaling axis.  
 
What We Have Learned from K5-Cre X Mdm2c/c Mice 
Chapter 2 describes the genetic ablation of Mdm2 in the epidermis of our 
Mdm2Δ/Δ mouse model.  The data obtained from these mice reinforce the results of 
previous tissue-specific Mdm2 knockout mice while contributing novel insights to the 
Mdm2-p53 signaling axis in tissue homeostasis.  Deletion of Mdm2 in the epidermis 
resulted in dramatic phenotypes in aged Mdm2Δ/Δ mice.  While the timing and specificity 
of the p53 responses differ between the conditional Mdm2 knockout studies (see Table 
1.1), our results corroborate the important role of Mdm2-dependent regulation of p53, but 
not p63, to ensure proper cellular function regardless of the tissue type that was analyzed.   
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It was previously known that genetic deletion of Mdm2 results in the activation of 
tissue-specific p53 responses.  For example, Mdm2 ablation in bone led to osteoblast cell 
cycle arrest, whereas, deletion of Mdm2 in the heart resulted in cardiomyocyte apoptosis 
(Lengner et al., 2006; Grier et al., 2006).  Notably, the cellular senescence observed in 
aged Mdm2Δ/Δ epidermal stem cells had not been previously observed as the primary 
response to Mdm2 deletion in any other tissue.  The explanations for why certain p53 
target genes and functions are activated in Mdm2 ablated tissues remain unresolved.  It is 
likely that the numerous epigenetic changes that have been shown in epidermal stem cells 
may affect the specific target genes or signaling pathways that are activated in response 
to stress (Mulder et al., 2012).  In tumors harboring wild-type p53, these tissue-specific 
responses may prove to be critical factors when considering therapies that activate p53 in 
various affected tissues.    
 
The epidermis proved to be a unique tissue to study the roles of Mdm2 and p53 in 
stem cell function and premature aging in mice.  A key feature of our Mdm2Δ/Δ mouse 
model is that the lifespan of these mice is relatively unchanged compared to controls.  To 
date, Mdm2 deletion in the small intestine has been the only other such model to display 
long-term survival (see Table 1.1).  However, the survival in the intestinal model is most 
likely due to the negative selection of cells that ablated Mdm2 via apoptosis, thus 
eliminating the cells of interest (Valentin-Vega et al., 2008).  The rare premature deaths 
that were seen in the Mdm2Δ/Δ cohort were due to persistently open wounds likely 
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resulting from conventional grooming, which allowed the majority of the mice to be 
studied and observed throughout their lifespan.  
   
Another advantage of the epidermis is the ease with which one can noninvasively 
assess stem cell function.  The results of wound healing and hair regrowth experiments 
accurately reflect the function of epidermal stem cells while causing minimal pain to the 
animals (Figures 2.17 and 2.18).  The survival of the Mdm2Δ/Δ mice allowed epidermal 
stem cell function in the absence of Mdm2 to be properly assessed and enabled the 
proposed role of Mdm2 regulation of p53 in preventing premature aging phenotypes to be 
substantiated.  The characteristics of this tissue may allow future genetic manipulations in 
the epidermis and potential drug treatments in the skin to be effectively studied while 
avoiding the lethality and severe atrophy seen in other tissues.   
 
Further studies using the Mdm2Δ/Δ mouse model can be done to address some 
unanswered questions.  While p53 protein levels and senescence-specific p53 target 
genes were upregulated in the skin of older Mdm2Δ/Δ mice, it is still unknown if the aging 
phenotypes are truly p53-dependent.  Unfortunately, crossing the Mdm2Δ/Δ model onto a 
p53-/- background would result in death before the premature aging phenotypes would 
arise due to tumorigenesis, and crossing the Mdm2Δ/Δ model onto a p53+/- background 
would not determine if the effects were solely p53-dependent.  Alternatively, the 
Mdm2Δ/Δ model could be crossed to a conditional p53 knockout mouse model so that p53 
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could be specifically ablated in older mice.  However, the timing of p53 deletion to 
ensure stem cell function and avoid potential spontaneous tumor formation would be 
difficult to determine.   
 
We proposed that the phenotypes arising in the older Mdm2Δ/Δ mice were due to 
the inability of stem cells to self-renew and replenish progenitor cells in hair follicles and 
the interfollicular epidermis.  The delayed timing of the phenotypes that we observed in 
Mdm2Δ/Δ mice fits this “premature stem cell exhaustion” hypothesis because normal 
epidermal stem cell turnover is between 12-14 months.  If this was the case, then forcing 
the epidermal stem cells to renew earlier than normal should result in even earlier 
premature aging phenotypes compared to untreated Mdm2Δ/Δ mice.  Continual hair 
shaving of young mice would drive the hair cycle and could determine whether the ability 
of epidermal stem cells to self-renew is truly affected in Mdm2Δ/Δ mice.  
 
Mdm2 regulation has been suggested to regulate overactive p53-induced 
organismal aging, however, less is known of the role of MdmX in this process.  As the 
tissue specific knockout of MdmX generally results in a less severe phenotype compared 
to the Mdm2 knockout in each respective tissue, it would be interesting to observe 
whether the same phenotypes occur in mice with epidermal MdmX deletion.  Similarly, 
concurrent ablation of Mdm2 and MdmX in the epidermis could determine whether one 
regulator was more important than the other in limiting p53 activity or whether they act 
synergistically to regulate p53 in the skin.  Since most tissue specific deletions of Mdm2 
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result in lethality, codeletion of Mdm2 and MdmX has only been tested in cells of the 
central nervous system (Xiong et al., 2006).  The lack of lethality in the Mdm2Δ/Δ model 
combined with the unique functional characteristics of the epidermis may provide a 
viable model to study Mdm2-MdmX-p53 dynamics in tissue homeostasis. 
 
Finally, it will be important to test the various Mdm2 and MdmX conditional 
deletion alleles in both previously tested and novel tissue types.  Because there are 
significant differences in the p53-dependent responses between the two described Mdm2 
conditional models (deletion of exons 5-6 versus exons 11-12 described in Table 1.1), the 
direct comparison of the phenotypes of these models in the same cell type are needed.  
Each of these models can also be used in parallel to test the dependence of Mdm2 in new 
cell types and functions such as regeneration of the liver.  Another approach would be to 
delete these regulators of p53 at different times during embryonic development and 
throughout the lifespan of the mice using different cre drivers.  These preliminary studies 
are just a few that can be asked using these conditional deletion mouse models and 
should lead to a greater overall understanding of the physiological regulation of p53 over 
time.   
  
What We Have Learned from Mdm2 S394 Knock-In Mice 
Chapters 3 and 4 describe the physiological role of Mdm2 Ser394 in a variety of 
p53-depedent responses.  We have shown that this residue is specifically critical in 
upregulating p53 stability and activity after DNA damage via γ-irradiation in multiple 
tissues of the Mdm2A/A and Mdm2D/D models.  As the p53 response to IR was also shown 
 119 
to be dependent on the activity of the ATM kinase (Figure 3.11), our data support ATM-
dependent Mdm2 Ser394 phosphorylation as a critical upstream regulatory modification 
that allows p53 to be stabilized so that downstream pathways such as apoptosis and cell 
cycle arrest can be activated. 
 
While the response to IR was profoundly affected in our Mdm2A/A and Mdm2D/D 
cells and tissues, the posttranslational status of Mdm2 Ser394 was unnecessary for the 
response to other DNA damaging agents.  The cytotoxic drugs etoposide, doxorubicin, 
and camptothecin inhibit topoisomerase enzymes resulting in increased DNA torsional 
strain and breaks (Wang, 1996).  However, the many differences that exist between these 
drugs and IR treatment may account for the functional differences that we observed in 
MEFs (Figures 3.24 and 4.1).  Firstly, the irradiation of cells lasts minutes, whereas the 
cytotoxic drugs were present in the media throughout the 18 hours of the assay.  This 
longer incubation time could result in more severe DNA damage and would not allow the 
cells to recover.  Likewise, the cytotoxic drugs are likely activating multiple signaling 
pathways that are able to activate p53 in a manner that is independent of ATM and, thus, 
independent on Mdm2 Ser394.  Further characterization of the response to varying times 
of exposure and doses of these drugs may uncover whether Mdm2 Ser394 
phosphorylation is truly dispensable for cell cycle arrest in MEFs.  The apoptotic 
response to these cytotoxic agents could also be tested in primary Mdm2+/+, Mdm2A/A, 
and Mdm2D/D thymocytes, but these cells are very sensitive to DNA damage and ATM-
independent effects may mask the role of Mdm2 Ser394.  As cytotoxic drugs and IR are 
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used in cancer therapies, it will be useful to know the exact pathways that are activated 
by each in order to predict the response of individual patients. 
 
Loss of Mdm2 Ser394 phosphorylation greatly reduced p53-mediated apoptosis in 
lymphocytes and growth arrest in MEFs but it did not completely abrogate these 
responses (as seen in p53-/- mice).  As anticipated by the literature, other modifications to 
Mdm2, MdmX, and p53 must also assist in regulating p53 functions after DNA damage 
(Chao et al., 2003; Sluss et al., 2004; Chao et al., 2006; Wang et al., 2009).  In agreement 
with this hypothesis, it is interesting to note the lack of p53 stabilization or p53 target 
gene activation in Mdm2D/D mice and cells in the absence of IR treatment (Figures 3.29-
3.31).  Although the absence of a p53 response in undamaged Mdm2D/D cells may reflect 
the inability of the substituted aspartate residue to perfectly mimic a phosphorylated 
serine residue (due to differences in the size and overall negative charge of these 
residues), equivalent levels of p53-mediated apoptosis and growth arrest are seen in 
Mdm2+/+ and Mdm2D/D cells after DNA damage.  Therefore, other DNA-damage induced 
signals in addition to Mdm2-S394 phosphorylation are required to fully activate the DNA 
damage response.  This interpretation also accounts for the viability of the Mdm2D/D 
mice, along with the similar growth characteristics and tumorigenic potential of 
undamaged Mdm2+/+, Mdm2A/A, and Mdm2D/D MEFs.  Due to the relatively modest effect 
seen in the Mdm2D/D model, the value of future attempts to mimic phosphorylated protein 
residues must be carefully considered.  Studies of serine-to-alanine knock-in mutations in 
mice have revealed clear roles for these phosphorylation sites in vivo, and the roles of 
successive sites should be investigated accordingly.    
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While the Mdm2A/A and Mdm2D/D models have confirmed a significant role for 
Mdm2 Ser394 in the p53 response to IR, further questions about the role of this residue in 
p53-dependent responses still remain.  Crossing these models onto a p53-null background 
would determine whether these effects are truly p53-dependent and would reveal whether 
the modification of Ser394 has an effect on p53-independent cellular processes.  
Likewise, these models could be bred to both Atm-/- and Wip1-/- mouse models.  Serine 
phosphorylation is a dynamic process, and the absence of a specific kinase or 
phosphatase shifts the balance to hypophosphorylated and hyperphosphorylated at each 
target site, respectively.  A recent study showed that codeletion of Wip1 and ATM 
partially rescued the phenotypes seen in Atm-/- mice, presumably due in part to the 
restoration of the balance of phosphorylated target sites (Darlington et al., 2012).  
Mdm2A/A, Wip1-/- and Mdm2D/D, Atm-/- mice would uncover whether the absence or 
constitutive presence of Mdm2 Ser394 phosphorylation could rescue some of the 
deleterious phenotypes in Wip1-/- and Atm-/- mice, and would reveal the relative 
importance of the Mdm2 Ser394 site in ATM-Wip1 signaling.  
 
Further analysis is also needed to determine ATM-Mdm2-p53 signaling in IR-
induced tumorigenesis.  The experiment presented in Figure 4.4 will need to be repeated 
with a range of IR doses.  As previous studies have shown that 4Gy IR can induce tumors 
in p53 deficient mice, it will be important to include irradiated p53-/- and p53+/- cohorts as 
a positive control for tumor development (Kemp et al., 1994).  It will be critical to 
control the irradiation conditions in all of the genotypes tested to eliminate the variability 
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that is inherent in the irradiation process.  Additionally, it has been shown that genetic 
background is a key determinant in the responses of mice to whole-body IR, and the 
newly generated inbred C57Bl/6 strains of the Mdm2A/A and Mdm2D/D knock-in mutants 
should be used to test these differences (Roderick et al., 1963; Lindsay et al., 2007).  It 
would be interesting to study the role of Mdm2 Ser394 in the organismal response to sub-
lethal IR doses and determine whether the increased survival observed in the Mdm2D/D 
mice is reproducible at multiple IR doses (Figure 4.4).  
 
The exact mechanism of action that accounts for how Mdm2 Ser394 
phosphorylation affects Mdm2 function also needs to be elucidated.  We used careful 
biochemistry experiments to determine whether this phosphorylation site affected Mdm2-
p53 protein interaction and Mdm2 E3 ligase activity after IR treatment in primary cells.  
However, the lack of results even in the positive controls in these assays indicated that 
the endogenous protein levels were too low and/or the reagents were not robust enough to 
generate a sufficient signal.  These limitations may preclude these assays from being 
performed in our in vivo setting, and co-overexpression of Mdm2 Ser394 mutated 
constructs and wild-type p53 in cell lines may be needed to further determine this 
mechanism.     
 
Additional experiments should be performed to ascertain the role of Mdm2 
Ser394 phosphorylation in cellular processes that are independent of exogenous IR 
treatments.  These include, but are certainly not limited to, the p53-dependent responses 
to ribosomal stress and oncogene activation.  Recent evidence has shown that the Mdm2 
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Zn finger is needed to activate the p53 response to ribosomal stressors such as 
actinomycin D and mycophenolic acid, but not to DNA damaging agents such as IR and 
doxorubicin (Macias et al., 2010).  As Mdm2 Ser394 is important in the DNA damage 
response, it would be important to determine whether there were overlapping 
mechanisms of p53 activation between ribosomal and DNA damage-induced stress 
responses.  If these stressors activate p53 in non-redundant ways, it could allow multiple 
strategies for anti-Mdm2 therapies in order to activate wild-type p53 in certain tumor cell 
populations. 
 
Finally, activated oncogenes are a known inducer of p53 activity and tumor 
suppressive function, and the essential role for p53 has been demonstrated in the Eµ-Myc 
transgenic mouse model (Eischen et al., 1999; Schmitt et al., 1999; Maclean et al., 2007; 
Garrison et al., 2008; Sluss et al., 2010).  Preliminary analysis of Mdm2A/+, Eµ-Myc and 
Mdm2A/A, Eµ-Myc mice suggest that the ability of Mdm2 Ser394 to be phosphorylated 
will be a critical determinant of lymphomagenesis development.  Previous work has also 
shown that absence of Wip1 in the Eµ-Myc model prolongs survival, presumably because 
ATM target sites are hyperphosphorylated due to the lack of this specific phosphatase 
(Shreeram et al., 2006b).  It will be interesting to generate Mdm2D/+, Eµ-Myc and 
Mdm2D/D, Eµ-Myc mouse cohorts to investigate the potential protective role of 
constitutive phosphorylation of the Mdm2 Ser394 residue against oncogene activation.     
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The Future of the Mdm2-p53 Field 
Much has been learned regarding the in vivo role of MDM-p53 signaling in 
development, in tissue homeostasis, and in tumorigenesis.  Work in mice has clearly 
demonstrated the importance of Mdm2 and MdmX in regulating p53 activity in normal 
cells and how perturbation of this pathway can readily lead to cancer.  Addressing stress-
induced modifications of Mdm2 and MdmX on MDM-p53 signaling in mice is a 
relatively new area of scientific exploration in the MDM field.  However, based upon the 
rather large phenotypic impact in mice of the few MDM modifications modeled to date, it 
would appear that the MDM-p53 signaling axis truly serves as a critical node for the 
conversion of stress signals into changes in p53 function, and further in vivo explorations 
of the effects of post-translational modifications to Mdm2 and MdmX are warranted.  A 
complete understanding of the upstream modifications that induce p53 activity would 
allow the response to specific therapies in tumors harboring wild-type p53 to be 
anticipated.   
 
Conclusions  
In conclusion, the mouse models presented in this dissertation have described 
novel roles of Mdm2 in a number of physiological contexts.  The Mdm2Δ/Δ mouse model 
linked premature aging phenotypes to disrupted Mdm2-p53 signaling, and Mdm2 deletion 
in the epidermis led to an increase in senescence and the loss of adult tissue stem cell 
function.  The Mdm2A/A and Mdm2D/D models demonstrated a key role for this 
posttranslational modification in the activation and duration of the p53 DNA damage 
response, and these mice will be used to further determine the role of Mdm2 Ser394 in 
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many p53-dependent and -independent cellular functions.  As our knowledge of the p53 
pathway and other diverse cell signaling pathways widens and deepens, the development 
and implementation of the proper combination of targeted therapies will be developed 
and utilized to treat different diseases not just limited to cancer. 
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